The EMG GOLD Podcast: Recent Episodes
EMG-Health
Join the GOLD team for a weekly exploration of all things pharma, featuring thought-provoking conversations, insightful interviews with high-profile industry guests and discussions about the latest trends and innovations taking the pharmaceutical sphere by storm.
Whether its marketing, medical affairs, the use of digital techniques to create patient-centric approaches or something in between, there's something here for anyone interested in the pharmaceutical industry.
In this episode, Isabel sits down with Richard Shotton, founder of Astroten and author of Hacking the Human Mind, to explore how behavioral science can help the pharmaceutical industry communicate more effectively and influence meaningful change.
In the show, Richard explains why understanding what really drives human behaviour matters more than relying on what people say. He discusses the power of social proof, trusted messengers and concrete storytelling, and shares why making the right behaviour easier can have a greater impact than simply making a stronger argument.
Guest bio Richard Shotton is a behavioural science expert, author, and founder of Astroten, a consultancy that helps organisations apply behavioural science to improve marketing effectiveness. He has worked with leading global brands including Google, Mondelez, Sky, and Santander, and is the author of bestselling books including The Choice Factory, The Illusion of Choice, and Hacking the Human Mind. Richard is also a regular columnist for Marketing Week, co-host of the Behavioral Science for Brands podcast, and an honorary fellow of the IPA.
This content has been funded by Angelini Pharma. In this episode, Isabel sits down with Rafal Kaminski, Chief Scientific Officer, Angelini Pharma, to explore how new science is reshaping brain health and what that means for patients.
In the episode, Rafal reflects on his path into neuroscience and explains how Angelini is building its brain health pipeline, with a focus on epilepsy. He discusses the promise of new treatment approaches, the role of partnerships in driving progress and why better care depends on more than medicine alone.
Guest bio
Rafal Kaminski is Chief Scientific Officer at Angelini Pharma, where he leads the company's research and development strategy across small molecules, biologics and RNA-based therapies. He joined Angelini Pharma in 2022 after more than 20 years in senior R&D roles at UCB Pharma, Roche and Molecure Therapeutics, leading drug discovery programmes from early research into clinical development.
A medical doctor with a PhD in Neuropharmacology, Rafal has authored more than 100 peer-reviewed publications and is an inventor on several patents. Outside of work, he is an avid music listener and vinyl collector and is married with one adult son.
In Part 3, Hideki Garren, Roche, shares a hopeful vision for slowing, stopping and ultimately preventing multiple sclerosis.
Guest bio
Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill Therapeutics, which he co-founded. He completed his neurology residency and postdoctoral fellowship at Stanford University, where he also served as an adjunct clinical professor. Hideki holds a bachelor's degree from Caltech and an MD and PhD from UCLA.
In Part 2, Hideki Garren, Roche, discusses the challenge of measuring MS progression and the importance of better data, imaging and patient insight.
Guest bio
Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill Therapeutics, which he co-founded. He completed his neurology residency and postdoctoral fellowship at Stanford University, where he also served as an adjunct clinical professor. Hideki holds a bachelor's degree from Caltech and an MD and PhD from UCLA.
This week, Isabel sits down with Hideki Garren, Senior Vice President and Global Head of Clinical Development, Neurology, Roche, to explore how our understanding of multiple sclerosis is changing and what that means for patients.
*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id= "request-WEB:a4937816-0c47-4273-9d15-60c7d4caba77-4" data-testid= "conversation-turn-10" data-scroll-anchor="true" data-turn= "assistant"> In Part 1, Hideki reflects on his path into neurology and explores the shift in how multiple sclerosis is understood, from relapses to ongoing progression. Guest bio
Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill Therapeutics, which he co-founded. He completed his neurology residency and postdoctoral fellowship at Stanford University, where he also served as an adjunct clinical professor. Hideki holds a bachelor's degree from Caltech and an MD and PhD from UCLA.
In Part 2 of the 2026 pharma forecast, the guests discuss the biggest unknowns for the year ahead and share a personal goal they're working towards in 2026.
Speaker bios Dheepa Chari
Vice President and Head of Global Scientific Communications, GSK
Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are delivered.
Emma Charles
Senior Vice President of European Markets, BMS
Emma oversees Bristol Myers Squibb's operations across 19 countries of Europe, bringing extensive global leadership experience spanning Europe, Asia, Latin America and the Middle East.
Yacin Marzouki
Omnichannel expert
Within the pharmaceutical sector, Yacin specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution.
Mary Stutts
CEO, Healthcare Businesswomen's Association
Mary leads a global organisation that advances representative leadership, strengthens the talent pipeline for healthcare and life sciences, and fuels business growth across the sector.
As 2026 gets underway, healthcare and life sciences face a year of both promise and pressure, with investment, innovation and equity all in sharp focus.
In Part 1 of this year's pharma forecast, four leaders explore where real opportunity lies, from health investment to personalisation and women's health, alongside the key threats that could slow progress.
Speaker bios Dheepa Chari
Vice President and Head of Global Scientific Communications, GSK
Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are delivered.
Emma Charles
Senior Vice President of European Markets, BMS
Emma oversees BMS operations across 19 countries, bringing extensive global leadership experience spanning Europe, Asia, Latin America and the Middle East.
Mary Stutts
CEO, Healthcare Businesswomen's Association
Mary leads a global organisation advancing the impact of women in healthcare, and is a prominent advocate for inclusive leadership, representative workforces and health equity.
This week, Isabel brings together three expert voices for an end-of-year round-up, reflecting on the moments that shaped healthcare and life sciences in 2025. Joined by Jonathan Sackier, Chairman, Medical Advisory Board, EMJ, Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, and omnichannel expert Yacin Marzouki, the conversation looks back on a year defined by both disruption and progress.
Across the episode, the contributors share their perspectives on the biggest setbacks and standout successes of the past 12 months, from regulatory uncertainty and access challenges to collaboration, innovation and scientific momentum. They also reflect on the lessons 2025 has taught them, and what those insights mean for patients, industry and the year ahead.
Speaker bios Hanna Svanbäck
Executive Director for Neuroscience, Eli Lilly
With over 15 years at Eli Lilly, Hanna leads Neuroscience operations across the UK, Ireland and the Nordics, driving scientific innovation and patient-centred research.
Jonathan Sackier
Chairman, Medical Advisory Board, EMJ
Jonathan is a surgeon by training and a founding partner of many start-ups in the medical technology space, as well as being the creator of the world's first operating room robot.
Yacin Marzouki
Omnichannel expert
Within the pharmaceutical sector, Yacin specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution.
In Part 3, Carol Pitcher-Towner, Alnylam Pharmaceuticals, explores how the pharmaceutical industry can become part of the solution. She highlights why leadership diversity matters, how trial design still excludes too many women and why embedding sex- and gender-aware science from day one could accelerate fairer, more effective care for everyone.
Speaker bio
Carol Pitcher-Towner is Senior Vice President and Head of Development Programs at Alnylam Pharmaceuticals. Since joining the company in 2014 as one of its first European regulatory leaders, she has gone on to oversee patient safety, risk management and Alnylam's global development portfolio. With more than 20 years of experience, including roles at AstraZeneca, Carol brings deep expertise across regulatory affairs and clinical development. She holds a PhD in Biological Sciences from the University of Warwick and was named an HBA Luminary in 2022 for her commitment to inclusive, patient-focused innovation.
This content was reviewed by Alnylam UK Ltd for compliance with regulations applicable to the pharmaceutical industry only.
In Part 2, Carol Pitcher-Towner, Alnylam Pharmaceuticals, breaks down the systemic forces driving inequity, from diagnostic bias to the lack of women in key specialties like cardiology, and explains how historical clinical trial exclusion continues to skew the science. Discover why representation isn't just a workforce issue: it's a scientific necessity, and the first barrier we must dismantle to ensure better care for everyone.
Speaker bio
Carol Pitcher-Towner is Senior Vice President and Head of Development Programs at Alnylam Pharmaceuticals. Since joining the company in 2014 as one of its first European regulatory leaders, she has gone on to oversee patient safety, risk management and Alnylam's global development portfolio. With more than 20 years of experience, including roles at AstraZeneca, Carol brings deep expertise across regulatory affairs and clinical development. She holds a PhD in Biological Sciences from the University of Warwick and was named an HBA Luminary in 2022 for her commitment to inclusive, patient-focused innovation.
This content was reviewed by Alnylam UK Ltd for compliance with regulations applicable to the pharmaceutical industry only.
This week, Isabel sits down with Carol Pitcher-Towner, Senior Vice President and Head of Development Programmes, Alnylam Pharmaceuticals, to unpack the gender inequities that continue to tarnish modern healthcare. Together, they explore the realities behind unequal outcomes and the steps needed to build a more inclusive future for patients.
In Part 1, Carol eveals the personal experiences that made gender inequity impossible to ignore and uncovers where today's biggest gaps still exist. From disease areas where women are routinely misdiagnosed to the persistent blind spots shaping clinical practice, this episode exposes the uncomfortable truths that are still costing lives, and why fixing them can no longer be optional.
Speaker bio
Carol Pitcher-Towner is Senior Vice President and Head of Development Programs at Alnylam Pharmaceuticals. Since joining the company in 2014 as one of its first European regulatory leaders, she has gone on to oversee patient safety, risk management and Alnylam's global development portfolio. With more than 20 years of experience, including roles at AstraZeneca, Carol brings deep expertise across regulatory affairs and clinical development. She holds a PhD in Biological Sciences from the University of Warwick and was named an HBA Luminary in 2022 for her commitment to inclusive, patient-focused innovation.
This content was reviewed by Alnylam UK Ltd for compliance with regulations applicable to the pharmaceutical industry only.
In Part 3, Hanna Svanbäck discusses the future of Alzheimer's care over the next five to 10 years, how trial design could be improved and reveals her opinion on the most exciting healthcare innovation on the horizon.
Speaker bio
Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly's long-standing commitment to advancing scientific innovation in this field. Hanna's passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester.
Follow us on Instagram: @emj.gold
In Part 2, Hanna Svanbäck discusses the latest and most significant innovations in Alzheimer's care. She also considers whether healthcare systems are prepared for the anticipated surge in cases, and shares some positive news about prevention.
Speaker bio Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly's long-standing commitment to advancing scientific innovation in this field. Hanna's passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester.
This week, Isabel sits down with Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, for an insightful discussion on the evolving landscape of Alzheimer's research. Together, they explore the latest breakthroughs, the challenges ahead and the strategies shaping the future of treatment and prevention.
In Part 1 of the conversation, find out about Hanna's journey into neuroscience, her work in Alzheimer's spanning three key markets and how her teams overcome the inevitable hurdles of brain-based drug discovery.
Speaker bio Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly's long-standing commitment to advancing scientific innovation in this field. Hanna's passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester.
In Part 3 of the conversation, Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business at Medtronic, talks about his outlook for the future of his field, his views on how the industry and clinicians can collaborate more effectively and the healthcare changes he is most excited about.
Guest bio
Giuseppe Savoja is Senior Business Director for Cardiac Surgery in Western Europe at Medtronic, where he leads the business with a focus on transformation, growth, and patient impact. With 20+ years in the medical device industry and leadership roles across Europe and Asia, he brings a blend of engineering expertise, commercial experience and a passion for developing high-performing teams. Born in Rome and having lived around the world, he's now back in the Italian capital with his family. Outside work, Giuseppe enjoys windsurfing, snowboarding, sailing and motorbiking.
Follow us on Instagram: @emj.gold
In Part 2 of the conversation, Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business, Medtronic, shares how ECMO has transformed over the decades and explores how clinicians and industry can work together to support the most vulnerable patients in intensive care.
Guest bio
Giuseppe Savoja is Senior Business Director for Cardiac Surgery in Western Europe at Medtronic, where he leads the business with a focus on transformation, growth, and patient impact. With 20+ years in the medical device industry and leadership roles across Europe and Asia, he brings a blend of engineering expertise, commercial experience and a passion for developing high-performing teams. Born in Rome and having lived around the world, he's now back in the Italian capital with his family. Outside work, Giuseppe enjoys windsurfing, snowboarding, sailing and motorbiking.
Follow us on Instagram: @emj.gold
This week, Isabel is joined by Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business at Medtronic, for a deep-dive into the evolution and future of ECMO, innovation in critical care and the realities of leading in the MedTech space.
In Part 1 of the interview, Giuseppe talks about what attracted him to the medical device industry, what his day-to-day role involves and what advice he would give to anyone considering joining the MedTech sector.
Guest bio
Giuseppe Savoja is Senior Business Director for Cardiac Surgery in Western Europe at Medtronic, where he leads the business with a focus on transformation, growth, and patient impact. With 20+ years in the medical device industry and leadership roles across Europe and Asia, he brings a blend of engineering expertise, commercial experience and a passion for developing high-performing teams. Born in Rome and having lived around the world, he's now back in the Italian capital with his family. Outside work, Giuseppe enjoys windsurfing, snowboarding, sailing and motorbiking.
Follow us on Instagram: @emj.gold
In Part 2 of this conversation, Robert Stewart, CEO, Theramex, explains how wider society can improve outcomes for women and reflects on the impact of decades of neglect in the field.
Speaker bio
Robert Stewart is CEO of Theramex, a global pharma company committed to supporting women's health across contraception, fertility, menopause and osteoporosis. With over 30 years of industry experience, he has held senior leadership roles at Amneal Pharmaceuticals, Allergan and Abbott Laboratories. A passionate advocate for improving representation and access in women's healthcare, Stewart is leading Theramex's mission to empower women through innovative solutions and meaningful change across the heathcare landscape.
Follow us on Instagram: @emj.gold
The EMJ GOLD podcast returns. To launch the series, Isabel is joined by Robert Stewart, CEO, Theramex – a global pharmaceutical company solely dedicated to women's health.
In Part 1 of this discussion, they unpack what inspired Rob's professional focus in this area and the role men can play in championing women's health.
Speaker bio
Robert Stewart is CEO of Theramex, a global pharma company committed to supporting women's health across contraception, fertility, menopause and osteoporosis. With over 30 years of industry experience, he has held senior leadership roles at Amneal Pharmaceuticals, Allergan and Abbott Laboratories. A passionate advocate for improving representation and access in women's healthcare, Stewart is leading Theramex's mission to empower women through innovative solutions and meaningful change across the heathcare landscape.
Follow us on Instagram: @emj.gold
Tune in as Isabel and Jade analyse the standout moments from EMJ GOLD’s guests this season, uncovering the challenges and opportunities shaping today’s pharmaceutical industry.
From self-advocacy at work and the future of personalised medicine to disease awareness, market access and making your marketing efforts stand out – they explore the season’s core themes, all backed by the latest industry data.
Watch our featured guest’s full episodes:
- GSK’s Dheepa Chari on the evolving sphere of scientific communication
- Yacin Marzouki on disrupting the traditional omnichannel model
- BMS’ Anita Gandhi on a decade of change in hematology
- Pfizer’s Richard Maughan on the future of access in the UK
- GSK’s Matt Mortimer-Ryan on behaviour-led pharma marketing
- Chiesi’s Shish Patel on COPD, the climate and improving care
- AbbVie’s Dr Daejin Abidoye on community and compassion in cancer care
- Bayer’s Dr Joana Reis on the promise of AI in breast cancer
How can industry close the screening gap in breast cancer? Find out in this episode, where Dr Joana Reis, Medical Affairs Breast Lead, Radiology, Bayer, explores some of the most significant challenges and opportunities in imaging today.
Together, Jade and Joana discuss her initial interest in a career in radiology, the pivotal role of professional societies in accelerating innovation, how AI is shaping the future of the field and much more.
A little more on EMJ GOLD’s guest…
Dr Joana Reis was appointed Medical Affairs Breast Lead for radiology at Bayer in January of 2025. Before this, she was the Medical Affairs Lead for digital radiology at the company, where she developed strategies focusing on AI applications in imaging. Before joining Bayer, Joana worked as a Senior Consultant Breast Radiologist at Akershus University Hospital in Oslo, Norway.
Tune in as Dr Daejin Adiboye, Vice President, Therapeutic Area Head, Solid Tumor Oncology, AbbVie, explores both the evolution of cancer care and his leadership style over the last two decades.
Together, Daejin and Jade discuss the lessons from his time in the clinic that shaped who he is today, the move to precision medicine in oncology, his work with the Cancer Support Community in San Francisco and much more.
A little more on EMJ GOLD’s guest…
Dr Daejin Abidoye serves as Vice President, Therapeutic Area Head for Solid Tumor Oncology at AbbVie. In this role, he is responsible for the clinical development of all assets in late oncology clinical development. His career includes over 20 years of experience in oncology, cancer research and drug development. Prior to joining AbbVie, Daejin was the Therapeutic Area Lead for Oncology Development and Clinical Research at Gilead Sciences. He has also held various roles at Seattle Genetics and Roche-Genentech. Dr. Abidoye is a board-certified oncologist with a career in clinical practice at Scripps Health in Southern California.
What is the environmental impact of respiratory illness? Find out in this episode of the EMJ GOLD podcast, where Shish Patel, Medical Director, Chiesi UK, joins Isabel to discuss the rising burden of COPD and the impact of respiratory care on the planet.
Together, the two explore the diagnostic gap in COPD, improving the experience of people living with the disease, balancing health innovation with climate concerns and much more.
A little more on EMJ GOLD’s guest…
Shish Patel trained as a pharmacist and has worked in the pharmaceutical industry for over 30 years. Currently, he serves as Medical Director at Chiesi UK and Ireland, and he has held senior positions within medical and scientific functions at both affiliate and global level throughout his career. In addition to his significant time at Chiesi, Shish has held positions at GSK and Sanofi. Shish also holds key industry board positions including at the Prescription Medicines Code of Practice Authority and the ABPI.
In this week’s episode of the EMJ GOLD Podcast, Matt Mortimer Ryan, Senior Global Marketing Manager, Vaccines, GSK, shares his perspective on how understanding patients’ emotional drivers can unlock more impactful, insight-led disease awareness campaigns.
Matt joins Isabel to discuss what true patient-centric marketing looks like in practice, how to translate behavioural insights into smarter strategies, the advice he’d give his younger self and much more.
A little more on EMJ GOLD’s guest…
Matt is a global marketing leader at GSK, driven by a passion for human-centered innovation in the pharmaceutical industry. With more than 20 years of experience at GSK, Pfizer and Danone, he combines his scientific curiosity with strategic creativity to accelerate meaningful outcomes for patients.
The views expressed in this interview are Matt Mortimer-Ryan’s own and do not necessarily represent those of GSK.
In this special edition of the EMJ GOLD podcast, Isabel and Jade dive into the latest insights from recent contributors and EMJ’s own data to uncover what healthcare professionals really want from medical affairs.
They explore the growing challenges of engaging HCPs, question whether there’s a gap between what HCPs say they want and what actually captures their attention and look ahead to what the future may hold.
Tune in for expert insights from guests including Dr Donatello Crocetta, Bora Erdemli, Cécile Janssenswillen, Dr Natalia Barkalina and Dheepa Chari.
This week, the team is joined by Richard Maughan, Senior Director and Head of UK Policy and Public Affairs, Pfizer, to explore how the UK is shaping access to medicine today, and what needs to change in the future.
From healthy ageing to the economic cost of respiratory infections, they dive into what the UK is getting right, where it’s falling short and why access to medicine matters now more than ever.
A little more on EMJ GOLD’s guest… Richard is Senior Director and Head of UK Policy and Public Affairs at Pfizer. His team works with public policymakers to deliver breakthroughs that change patients’ lives, spanning Pfizer’s broad medicines and vaccines portfolio, and deep science footprint. He is a member of Pfizer’s UK Senior Leadership Team and Europe Policy & Public Affairs Leadership Team.
Prior to Pfizer, Richard was Head of UK Government Affairs for Eli Lilly and Company. He has also worked at the Confederation of British Industry (CBI), the UK’s leading business lobbying group. He studied Politics at the University of Edinburgh and the University of California Santa Cruz, and grew up in north-east England.
This National Blood Week, the team sit down with Anita Gandhi, Vice President, Translational Development, BMS, to explore the last decade of innovation in hematology and what lies ahead for the space.
Together, Anita and Jade discuss Anita’s route into the pharmaceutical industry, the current unmet needs of patients with blood cancer, what the future of innovation looks like in hematology and what Anita’s HBA Rising Star Award means to her a decade on.
A little more on EMJ GOLD’s guest…
Anita is currently the Vice President of Translational Development at BMS, leading not only hematology translational development at the company, but solid tumour, immunology, cardiology and neurology as well. She has over 20 years of industry experience including drug discovery and translational development, and she was the recipient of the HBA Rising Star Award in 2015.
This week on the podcast, the team are joined by omnichannel engagement expert Yacin Marzouki, who shares his strategies on how to make omnichannel work for both pharmaceutical companies and healthcare professionals.
Together, Yacin and Jade sit down in the studio to explore what it takes to harmonise omnichannel across an organisation, why content activation is still a major hurdle, how to make sure messaging truly resonates with HCPs and much more. Expect practical insights on operational excellence, the evolving role of AI and a fresh perspective on what success looks like across a product’s lifecycle.
A little more on EMJ GOLD’s guest… Yacin Marzouki is a global omnichannel engagement lead on a mission to disrupt the industry’s approach to omnichannel. Within the pharmaceutical sector, he specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution. Yacin is dedicated to transforming brand plans into meaningful, measurable customer engagements, and is passionate about building high-performing, collaborative teams that deliver real impact.
The EMJ GOLD podcast is back for a new season! In the first episode of season 10, the team are joined by Dheepa Chari, Vice President and Head of Global Scientific Communications, GSK, to discuss the past, present and future of scientific communications.
Together, Dheepa and Isabel explore her journey from biostatistics to biopharma leadership — and the lessons learned along the way. They discuss what great science communication looks like, where it’s heading next and why storytelling still matters in a digital-first world. Plus, expect practical insights on cross-functional collaboration and the growing role of AI.
A little more on EMJ GOLD’s guest… Dheepa Chari is the Vice President and Head of Global Scientific Communications at GSK. Here, she leads strategy and execution across Oncology, Vaccines, Specialty Care and General Medicine, driving innovation in how scientific narratives are delivered across channels.
Before joining GSK in 2024, Dheepa held senior posts at Pfizer, Amgen and Novartis in both clinical and communications roles. Outside of work, Dheepa brings stories to life in a different way - as a singer-songwriter who regularly performs in New York City.
Season 10 is on the horizon, but before we release our first episode, why not tune in to some of Isabel and Jade’s favourite moments from season 9?
From leadership insights from top CEOs to navigating setbacks in R&D, there’s plenty to discover in this season’s batch of GOLD Medal Moments.
As well as the EMJ GOLD team, you’ll hear from four former guests:
Charl van Zyl, CEO, Lundbeck Pharmaceuticals
Dr Dennise Broderick, President and Managing Director, Galen Pharma
Rebecca Vermeulen, recipient of the Healthcare Businesswomen’s Association (HBA) STAR award for 2025
Christoph von der Goltz, Global Head of Medicine Central Nervous System and Emerging Areas, Boehringer Ingelheim
Join Isabel and Jade as they wrap up Season 9 of the podcast with special guest Dennise Broderick, President and Managing Director, Galen Pharma.
In this episode, Jade and Dennise discuss her move from academia to the pharmaceutical industry, her lifelong ambition to be a leader and how she approaches hard decisions in business.
A little more on EMJ GOLD’s guest… Dennise is Managing Director and President at Galen – a pharmaceutical company based in Northern Ireland focused on pain management, dermatology and gastroenterology. There, she is responsible for all the aspects of the company’s operations, marketing and governance across its various sites throughout the UK and Europe. Previously, Dennise has held positions at Pfizer, Hospira, Zeneus and Viatris – most recently working as the Country Manager at Ipsen.
How can pharmaceutical companies best navigate setbacks in drug development to deliver breakthroughs in R&D? Find out in this week’s episode, where Isabel and Jade share an interview with Christoph von der Goltz, Global Head of Medicine Central Nervous System and Emerging Areas, Boehringer Ingelheim.
Together, he and Jade explore the ins and outs of drug failure, whether to pivot or persevere after an R&D setback, how to better break the stigma of mental illness and much more.
A little more on EMJ GOLD’s guest…
Christoph von der Goltz is Global Head of Medicine Central Nervous System and Emerging Areas at Boehringer Ingelheim. He has more than 15 years of experience in a variety of roles in pharmaceutical R&D. He is also a board-certified psychiatrist with more than 10 years of clinical experience in neurology and psychiatry and academic research in preclinical, clinical and public health projects in Germany and Sweden.
Join Isabel and Jade this week as they delve into lessons in leadership and patient centricity with Rebecca Vermeulen, recipient of the Healthcare Businesswomen's Association (HBA) STAR award for 2025.
Rebecca shares her journey from pharmacist to industry leader, discussing her approach to leadership, the current landscape for women in pharma and what effective patient centricity looks like in practice.
A little more on EMJ GOLD’s guest
Rebecca was recently awarded the STAR prize by the Healthcare Businesswomen’s Association in recognition of her outstanding contributions to the organisation’s growth, influence and impact. Her win highlights her leadership, particularly during her time as the HBA Global Board Chair throughout the pandemic.
She has spent over 30 years working in the industry and has served in a variety of functions including medical affairs, clinical research, sales and medical communications.
Join Isabel and Jade as they uncover how AI is shaking up the radiology space and beyond with Naiara Martínez Cabrera, Vice President, Global Marketing, DeepHealth.
Together, Naiara and Jade explore what first drew the marketing leader to the healthcare sector, why radiology in particular has seen such a boost from artificial intelligence, what other therapy areas can learn from space and much more.
A little more on EMJ GOLD’s guest… Naiara Martínez Cabrera is Vice President of Global Marketing, DeepHealth, where she has been since the company’s inception in 2023. Prior to this appointment, she worked at Philips in roles such as Head of Communications and Head of Downstream Marketing for Precision Diagnosis.
This week, join Isabel and Jade as they explore what’s on the horizon for cardiac care, focusing on the revolutionary impact of remote monitoring with Angelo Auricchio, Chief Medical Officer, Rhythm Management, Boston Scientific.
He and Isabel discuss Angelo’s recent career change into the industry, how technology could reform the UK’s NHS, the role of remote monitoring in patient wellbeing and more.
A little more on EMJ GOLD’s guest… Angelo Auricchio was appointed Chief Medical Officer, Rhythm Management, Boston Scientific in September 2024, where he works across the EMEA region. Prior to his time in industry, he gained a wealth of experience in academia and medicine, serving as Editor-in-Chief of the European Society of Cardiology’s journal EP Europace and President of the European Heart Rhythm Association.
During his time in the medical field, he also served as Deputy Head of the Cardiology Department and Director of the Clinical Electrophysiology Unit at the Istituto Cardiocentro Ticino in Switzerland.
Join Isabel and Jade as they explore the persistent misunderstandings of women’s health in modern medicine with Mary Stutts, CEO of the Healthcare Businesswomen’s Association.
In this episode, Mary unpacks the key findings of the HBA’s latest report, which exposes critical gaps in doctors’ understanding of women’s health. She discusses the root causes, the real-world consequences and what the pharmaceutical industry must do to drive meaningful change.
A little more on EMJ GOLD’s guest…
Mary is the CEO of the HBA, a global organisation with a mission is to promote the advancement and impact of women in healthcare. She is a leading voice in the industry, advocating for inclusive leadership, representative workforces and health equity. Prior to joining the HBA, she worked for Genentech, Bristol Myers Squibb, Bayer and other pharmaceutical organisations.
She is also an accomplished author, having published her books ‘Recurring Themes of Exclusion in the Workplace’ and ‘The Missing Mentor: Women Advising Women on Power, Progress and Priorities’.
Why do we forget? Join Isabel and Jade as they explore the science behind memory, recall and retention, and uncover why interactive content could be the key to making information stick.
In this episode, discover how interactivity enhances learning, helps HCPs recognise the value of new therapies and ultimately improves patient care. Read our article exploring the topic further here. And if you’re interested to see how interactive works in the medical context, check out the interactive article mentioned here.
Join Isabel and Jade for part two of their World Cancer Day special for 2025, where guest Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson, uncovers more of his insights into the oncology space.
In this instalment, Martin shares his thoughts on improving access to innovative cancer medicines, improving public trust toward the industry and his personal leadership style.
A little more on GOLD’s guest… Martin Price is Vice President for Health Economics, Market Access and Reimbursement in Europe, the Middle East and Africa, Johnson & Johnson, a role he has held for the past eight years. He leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Johnson & Johnson’s new products and indications. Prior to this, Price worked in Johnson & Johnson’s UK affiliate, latterly as director of external affairs, where he was responsible for market access, communications and government affairs. He joined Johnson & Johnson in 2001 from GlaxoSmithKline, where he began his career as senior health-outcomes manager.
Join Isabel and Jade as they present a special World Cancer Day 2025 edition of the podcast. They are joined by Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson.
In this first instalment of the conversation, Martin and Jade discuss this year’s theme ‘United by Unique’, the increasing importance of real-world evidence in oncology and improving access to innovative cancer medicines.
A little more on GOLD’s guest… Martin Price is Vice President for Health Economics, Market Access and Reimbursement in Europe, the Middle East and Africa, Johnson & Johnson, a role he has held for the past eight years. He leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Johnson & Johnson’s new products and indications. Prior to this, Price worked in Johnson & Johnson’s UK affiliate, latterly as director of external affairs, where he was responsible for market access, communications and government affairs. He joined Johnson & Johnson in 2001 from GlaxoSmithKline, where he began his career as senior health-outcomes manager.
The EMJ GOLD podcast is back for a new season! In the first episode of Season 9, the team are joined by Charl van Zyl, President and CEO, Lundbeck Pharmaceuticals, to discuss advances in the treatment of neurological disorders, making this the 'decade of the brain', and how industry can do more to support patients living brain conditions.
Together, Charl and Isabel explore his career journey in the pharmaceutical industry, Lundbeck’s plans for the future, the role of digital health technology and much more.
A little more on EMJ GOLD’s guest...
Charl van Zyl joined Lundbeck as President and CEO in September 2023. He brings more than 23 years of experience from commercial international management roles within the pharmaceutical industry, most recently in the field of immunology and neurology from UCB where he served as Executive Vice President and Head of Neurology globally, responsible for corporate activities in Europe and international markets.
Charl is British and holds a degree in Medical Biochemistry from the University of Cape Town, South Africa. He has lived and worked in South Africa, United States, Japan, Switzerland, Belgium and now Denmark.
Curious to discover what might lie ahead for industry in 2025? Join Isabel and Jade in this special episode of the EMJ GOLD podcast as they reflect on whether last year’s predictions for 2024 came true, while three special guests share their predictions and hopes for pharma in the year ahead.
The line-up includes Jennifer Schranz of Ipsen, Mercedes Diz of Almirall and EMJ’s own Dr Jonathan Sackier - all of whom share their predictions in their areas of expertise.
A little more on GOLD’s guests…
Jennifer Schranz is the Senior Vice President, Global Head of Rare Diseases at Ipsen, where she oversees the Rare Diseases therapy area with a focus on R&D strategy and execution. During her time at the business, she has led talented teams of scientists and fostered strong internal collaborations within the company, leveraging her clinical development expertise to advance Ipsen’s vision of addressing challenging rare diseases.
Mercedes Diz has over 20 years’ experience in the pharmaceutical industry, having graduated with a degree in Biochemistry and Molecular Biology from the Autonomous University of Madrid. She has worked in a number of different pharmaceutical companies, from J&J to Pfizer, and is also a keen member of the Healthcare Businesswomen’s Association. At Almirall, she leads portfolio strategy and commercial innovation for global brands, new products and digital and cultural transformation.
Dr Jonathan Sackier is Chairman at EMJ and the host of the EMJ podcast, where he utilises his experience as a physician to discuss the latest breakthroughs and challenges in the medical field with fellow practitioners and experts. Jonathan is a founding partner of many start-ups in the medical technology space and created the world’s first operating room robot.
As 2024 comes to a close, it's time to look back on a year in the pharmaceutical industry. In this final episode of the year, Isabel and Jade are joined by three former guest to reflect on the pivotal moments that defined the past 12 months.
They are joined by Jennifer Schranz from Ipsen, Martina Dempsey from Astellas and Elias Revonta, CEO of Orcason, who all return to the podcast to share their insights. Together, they’ll discuss the major trends, challenges and breakthroughs that shaped 2024, including advancements in oncology, gene therapy, rare diseases and the growing role of AI.
A little more on EMJ GOLD's guests...
Jennifer Schranz is the Senior Vice President, Global Head of Rare Diseases at Ipsen, where she oversees the Rare Diseases therapy area with a focus on R&D strategy and execution. During her time at the business she has led talented teams of scientists and fostered strong internal collaborations within the company, leveraging her clinical development expertise to advance Ipsen’s vision of addressing challenging rare diseases.
Martina Dempsey is the Vice President of Commercial Strategy & Operations at Astellas Europe, having worked with the business since 2014 in her home country of Ireland. In addition to her role at the pharma company, she also acts as a Board Member for the Irish Pharmaceutical Healthcare Association. Prior to her time at Astellas, she spent 13 years at GSK in various roles including in the regulatory affairs and business transformation sectors.
Elias Revonta is the Founder and CEO, Orcason Medical, where he is supported by a strong background in the medical device industry – spanning over 20 years in various leadership roles from sales to product development. He is passionate about transforming and democratising healthcare with modern and easy-to-use diagnostic tools that serve all demographics.
In this final episode of the season, Isabel discusses how to normalise the conversation, not the suffering, around menopause with Dr Cecilia Caetano, Vice President, Head, Global Medical Affairs, Women’s Health, Bayer.
Menopause affects over 50% of the world’s population, but its symptoms and effects are often misunderstood or ignored. Find out how industry can help by equipping not only HCPs but also women with the knowledge and awareness to manage menopause on an individual level, debunking the myths and prejudices surrounding the topic and much more.
Season 8 is almost over, but before we release our finale episode, why not take a listen to some of our favourite moments from the last couple of months?
From an insight into why Gen Z might be turning their sails towards the pharmaceutical industry, to a call for a better understanding of HIV stigma, there’s plenty to discover in this season’s GOLD Medal Moments.
In this episode of the EMJ GOLD podcast, Jade and Isabel explore one of the most urgent global health issues: antimicrobial resistance (AMR). As part of World AMR Awareness Week, they are highlighting this year’s theme ‘Educate. Advocate. Act now’.
Joining the conversation is Elias Revonta, Founder and CEO, Orcason Medical, who shares his vision for tackling AMR through groundbreaking medical technology. Orcason Medical is pioneering point-of-care devices for ear, nose and throat conditions to address the overprescription of antibiotics—a vital measure in the fight against AMR.
A little more on GOLD’s guest… Elias Revonta is the Founder and CEO, Orcason Medical, where he is supported by a strong background in the medical device industry – spanning over 20 years in various leadership roles from sales to product development. He is passionate about transforming and democratising healthcare with modern and easy-to-use diagnostic tools that serve all demographics. With a mission to combat the rise of AMR, his goal is to protect the power of antibiotics and improve the lives of millions of patients by enabling smarter, safer healthcare solutions.
In this episode, Isabel welcomes Patrick Oliver, General Manager for the UK and Ireland at Alfasigma, to explore the company’s exciting entry into the UK market and the evolving landscape of healthcare in the country.
In the conversation, Patrick brings his wealth of industry experience to share his vision for Alfasigma’s future, the potential he sees in the UK healthcare market and the unique challenges ahead. They also delve into Lord Darzi’s report on the NHS, examining its implications for healthcare reform and innovation.
A little more on GOLD’s guest…
Patrick Oliver is Alfasigma’s General Manager for the UK & Ireland, a role he’s held since the company’s launch in the UK in early 2024. He has 36 years’ experience in the industry, with 16 years specifically in market access. Prior to joining Alfasigma, Patrick worked in market access for a number of large pharmaceutical companies including Johnson & Johnson, AbbVie and Abbott.
As 2024 draws to a close, what should pharma teams be focusing their budgets on for the final quarter of the year?
Join Jade and Isabel as they explore the critical trends that have shaped the industry in 2024. As teams finalise their budgets and plan for the final quarter and year ahead, this conversation brings insights into how strategies like personalised engagement, thought leadership and interactive, on-demand content are making an impact. With real-life examples, learn about the tools you can invest in to end the year on a high.
In this new episode, the team welcomes Jennifer Schranz, Senior Vice President, Global Head of Rare Diseases, Ipsen, to investigate the burden faced by women with rare diseases.
Together, Jennifer and Jade discuss how the industry can address challenging rare diseases and making a meaningful impact on patients’ lives, the double jeopardy that women with rare diseases face, recent breakthroughs in the space and much more.
In the latest episode of our podcast, we welcome Richard Lowenthal, CEO, ARS Pharmaceuticals, to explore the company’s mission to address unmet needs in allergy care.
During the conversation, Richard shares insights into his early career at the FDA and the regulatory challenges he faced in bringing ARS’s new nasal spray to treat severe allergic reactions to market. He also discusses the future direction of the company and much more.
A little more on EMJ GOLD’s guest… Richard Lowenthal is the co-founder, President, and CEO, ARS Pharmaceuticals, with a leadership role since the company’s inception in 2015. Before ARS, he founded Pacific-Link Regulatory Consulting, where he contributed to the development of their diazepam nasal spray. Richard’s extensive background includes senior roles at Cadence Pharmaceuticals, Maxim Pharmaceuticals and Janssen Research Foundation, as well as work as a chemist at the FDA. He holds an M.Sc. in organic chemistry and an MSEL and has chaired the American Association of Pharmaceutical Scientists.
In the latest episode, Jade sits down with Martina Dempsey, Vice President of Commercial Strategy and Operations at Astellas Europe, to discuss empowering women in the pharmaceutical industry.
They explore how pharma meets the needs and values of young graduates, the ongoing challenges women face in securing leadership roles, the critical impact of mentorship on career development and much more.
In this episode, Isabel is joined by Nedim Pipic, Senior Vice President and Global Therapeutic Area Head for Mental Health, Boehringer Ingelheim, to mark World Mental Health Day on 10 October 2024.
Their conversation dives into the unique challenges faced by those living with serious mental illnesses, the impact of media representation and the role pharma can play in transforming treatment and quality of life for these patients.
Central to their discussion is the importance of amplifying lived experiences, a key focus of Boehringer’s new campaign, Schizophrenia in Real Life: Stories of Challenges, Resilience, and Hope. The campaign aims to build greater understanding and acceptance of the condition by highlighting the strength and resilience of those living with it.
This week, Jean-Bernard Simeon, Senior Vice President and Head, ViiV Healthcare Europe, sits down with the EMJ GOLD team to share his thoughts on the current landscape for patients with HIV in Europe.
Together, JB and Jade explore the UNAIDS roadmap to end the HIV epidemic by 2030, the barriers faced by people living with HIV in Europe, stigmas still surrounding the condition and much more.
The EMJ GOLD podcast is back! In the first episode of season 8, Jade sits down with Chantal Friebertshäuser, Senior Vice President and General Manager, EMEAC, Moderna, to discuss how Europe can combat the recent erosion of trust in vaccines.
Together, the two explore the role of governments in addressing vaccine hesitancy, improving vaccine education amongst various groups, how a culture of collaboration can improve the current vaccine landscape and much more.
The new season of the podcast is only a week away, so before we get started – why not have a listen to some of the best bits from Series 7? From a deep dive into women’s health to why the industry thrives on a little healthy competition, there’s plenty to discover in last season’s highlights.
As well as the EMJ GOLD team’s analysis of the key themes, you’ll hear from six former guests:
- Mercedes Diz, Chief Marketing Office, Almirall
- Nichole Davies, Global Chief Strategy Officer, VML Health
- Edmond Chan, Senior Director, EMEA TA Lead, Haemato-Oncology, J&J
- Stefan Woxström, Senior Vice President, Europe and Canada, AstraZeneca
- Danie Du Plessis, EVP, Pharmaceutical Operations, Kyowa Kirin
- Harmony Garges, Chief Medical Officer ViiV Healthcare.
In this season finale of the EMJ GOLD podcast, Isabel speaks to Dr Tadaaki Taniguchi, Chief Medical Officer, Head of Medical and Development, Astellas Pharma, about how he strives to challenge the status quo in the pharmaceutical industry.
The two discuss how Tadaaki’s time as a surgical oncologist has influenced his leadership style, how collaboration is key for making impacts for patients, the next game changers in cancer treatment and more.
A little bit more on EMJ GOLD’s guest… Dr Tadaaki Taniguchi leads Astellas’ global team in identifying, discovering and developing new treatments that have the potential to transform healthcare, with a focus on innovative and patient-centred therapies.
He has more than 20 years of industry experience spanning research, development and medical affairs, and has worked in a range of therapeutic areas including diabetes and oncology. Prior to joining Astellas, Tadaaki held senior positions at other major pharmaceutical companies in the US, Japan and China. Before joining the industry, he spent 10 years as a surgical oncologist – giving him a unique perspective on how to deliver breakthrough science that changes the way diseases are treated.
In this penultimate episode of Season 7, Isabel and Jade sit down to discuss EMJ GOLD’s most recent features of the month – our infographic on optimising pharma’s customer experience journey and an article on how exactly to design this experience.
Within the episode, the team explore how the industry may be missing out on insights gathered from HCPs, what makes a ‘winning’ website for HCPs and more – featuring exclusive input from Robert Tegge, Associate Principal, ZS, who shares valuable insights on what HCPs are really looking for before and after a congress.
A little more on EMJ GOLD’s guest… Robert Tegge is a leader within the ZS meetings and events practice area, which focuses on identifying insights to drive improved outcomes for our clients’ meetings programs. He collaborates with organizations to help build capabilities and solve unique problems, leveraging ZS’s technology and operations infrastructure as well as industry expertise.
Robert has a wealth of experience in strategy and operations roles across various healthcare sectors, including providers, pharmaceuticals, and medical products. In these roles, he has consistently leveraged data to provide actionable insights on a variety of sales, marketing, and growth decisions. He also holds a B.S. and an M.S. in civil engineering from the University of Illinois at Urbana-Champaign, and an MBA from Northwestern University’s Kellogg School of Management.
In this week’s edition of the podcast, Isabel and Jade share an interview with Dr Harmony Garges, Chief Medical Officer, ViiV Healthcare. She speaks with Dr Jonathan Sackier, Host, EMJ Podcast, who joined us in Reuters Barcelona where we meet our guest.
Together, the two discuss Harmony’s decision to join the pharmaceutical industry, how treating children with HIV needs to be approached differently, her views on improving vital access to HIV treatment and much more. This is the longer version of her Catalyst interview with us, check that out here.
In this week’s episode, Danie du Plessis, Executive Vice President, Pharmaceutical Operations, Kyowa Kirin, sits down with the EMJ GOLD team to share the value that patient partnerships can hold in the industry.
Danie explores how patient partnerships have evolved over the years, what companies should be doing to get them to their best potential, the value of learning from others and much more.
A little more on EMJ GOLD’s guest… After completing his medical studies and a Master’s Degree in Clinical Pharmacology in South Africa, Danie spent three years working in a primary care setting including his own private practice. He joined the pharmaceutical industry in 1993, worked in medical affairs, marketing and sales, pharmacovigilance and clinical operations. He has held roles such as including Senior Vice President and Head of Worldwide Medical Affairs at GlaxoSmithKline. Danie joined Kyowa Kirin International in August 2019 as head of Medical Affairs and has been Executive Vice President Pharmaceutical Operations since April 2024.
He is also a Director and Chair of the Global non-profit Medical Affairs Professional Society (MAPS) Board, Fellow of the Faculty of Pharmaceutical Medicine in the UK, visiting senior lecturer at King’s College, London and an affiliate member of the Association for Professional Executive Coaching and Supervision (APECS).
Tune in to the latest episode of the EMJ GOLD podcast as Isabel and Jade cross the halfway point of the season with special guest host Dr Jonathan Sackier of the EMJ podcast.
In this episode, the team listen back to Jonathan's discussion with Stefan Woxström, Senior Vice President Europe and Canada, AstraZeneca at Reuters Events: Pharma 2024 in Barcelona. Together, the two unpick the current small molecule funding landscape, how to improve incentives to invest in rare diseases, how to better inform policymakers about the difference they can make and much more.
A little more on EMJ GOLD’s guest…
In Stefan’s role as SVP Europe and Canada at AstraZeneca, he is dedicated to supporting teams across 30 markets to grow the company ethically and sustainably. His focus is to improve the lives of millions of patients, with a particular emphasis on partnering to find solutions to healthcare challenges, addressing the burden of chronic disease and transforming health systems to be more future-proofed and resilient.
He’s worked at AstraZeneca for over 28 years, having joined before the merger of Astra and Zeneca in 1999, and holds a BSc and MSc in Business Administration & Economics from Stockholm University. He has additionally sat on the boards of multiple corporations, including The Swedish Chamber of Commerce and Industry in Japan, the EFPIA and most recently the Swedish Swiss Chamber of Commerce.
This week, Claire D'Abreu-Hayling, Chief Scientific Officer, Sandoz, joins Isabel on the podcast to share how leading with love rather than ruling with an iron first is the best way to get results in the pharmaceutical industry.
In this episode, Claire and Isabel discuss how she fell in love with science as a child, the leadership skills she has gained over the course of her career and the importance of valuing your people and being valued in return.
A little more on EMJ GOLD’s guest… Claire D'Abreu-Hayling is the Chief Scientific Officer at Sandoz, and with more than 30 years of experience in the pharmaceutical industry under her belt, she knows a thing or two about life sciences leadership - past and present. At the company Claire oversees the global product development network where she manages infrastructure strategy, pipeline execution and talent acquisition for both small molecules and biosimilars. Outside of work, Claire is a true champion of authenticity in the workplace. She is passionate about diversity, equity and inclusion and is particularly committed to mentoring Black and Asian women who are pursuing careers in STEM.
Join EMJ GOLD for a special edition of the podcast, in which Isabel is joined by Tim Uden, Creative Director, EMJ to discuss the new frontier of medical education tools and skills.
In this episode, the two explore how new technological offerings, such as interactive articles, are transforming the space for medical content – enabling content creators to share research in a more impactful way and helping healthcare professionals better engage with and continue their professional development.
Check out EMJ’s interactive article mentioned in the podcast: JAK inhibitors: a new frontier in dermatology
Join EMJ GOLD for a special edition of the podcast, in which Isabel is joined by Tim Uden, Creative Director, EMJ to discuss the new frontier of medical education.
In this episode, the two explore how innovative content formats, such as interactive articles, are transforming the medical content landscape. These advancements help healthcare professionals better engage with and continue their professional development, enhance knowledge retention, and provide greater control over how they learn.
As we approach the end of Pride month, Jade explores how the pharmaceutical industry can best staff and patients who identify as part of the LGBTQ+ community. She talks with Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology, J&J, who shares his personal views on how the industry can improve health outcomes and encourage authenticity.
In this interview, they discuss how both the pharmaceutical and healthcare industries can do their best to support people from the LGBTQ+ community, the unique challenges that patients and staff may face and more.
A little more on GOLD’s guest…
Edmond has been with J&J for just over ten years, starting in pharmacovigilance before moving into medical affairs. During this time, he has worked in the areas of diabetes and immunology before recently settling into his current area of expertise, haemato-oncology.
Edmond also works as an ABPI final signatory and holds a PhD in Medical Research in Therapeutic Antibodies as well as a Masters in Medical Statistics. He also has 12 years’ experience in clinical practice.
At the heart of all these academic and professional achievements, Ed is also a proud member of the LGBTQ+ community and strives to be a role model for other members.
With Season 7 in full swing, Isabel dives deep into the fascinating world of women’s health with Nichole Davies, Chief Strategy Officer, VML, to uncover the truth behind why women live longer but in poorer health and how the industry can incite change.
In the interview, they discuss the rise of FemTech, the challenge of funding and reimbursement, the role men can play in moving the conversation up the agenda and more.
A little more on GOLD’s guest… Nichole leads the strategic disciplines and teams for the global VML Health network, overseeing research and development for all client and agency strategy and messaging. With over 20 years in the healthcare industry, she has worked in cities including London, New York, San Francisco, and Singapore. Nichole previously led strategy for Wunderman Thompson Health, Grey Health and Interbrand Health, following a decade in consulting.
Her experience covers diverse areas such as oncology, immunology, rare diseases, respiratory health, women's health, diabetes and nutrition. Nichole has collaborated with industry leaders like AstraZeneca, Pfizer and Johnson & Johnson.
Nichole graduated with honors in Chemistry from UMIST and completed her Postgrad in Marketing at London Business School. A Chartered Marketer, she is dedicated to driving change for improved patient outcomes and has worked with the Department of Health on patient communication standards.
The GOLD podcast is back and better than ever! Tune in as Isabel and Jade unveil GOLD's new brand identity 'EMJ GOLD' and enter Season 7 with new energy, new insights and on camera for the first time!
But who is the season's first guest? Meet Mercedes Diz, Chief Marketing Officer, Almirall, who spoke to Jade at the Reuters Pharma 2024 event in Barcelona earlier this year. In the interview, Jade asks Mercedes about Almirall's move from respiratory health to dermatology, pushing your limits to achieve your goals and how the industry can work to go beyond the surface to support patients with dermatological concerns.
A little more on GOLD’s guest… Mercedes Diz has over 20 years' experience in the pharmaceutical industry, having graduated with a degree in Biochemistry and Molecular Biology from the Autonomous University of Madrid. She has worked in a number of different pharmaceutical companies, from J&J to Pfizer, and is also a keen member of the Healthcare Businesswomen's Association. At Almirall, she leads portfolio strategy and commercial innovation for global brands, new products and digital and cultural transformation.
Join Isabel and Jade for this special episode of the GOLD podcast as three of last year's guests share their predictions for the pharmaceutical industry in 2024. The panel includes Matt Lewis from Inizio, Rick Hollis from Ipsen and Claudia Martinez from the Access to Medicine Foundation, all of whom share their predictions in their areas of expertise.
But that's not all. The GOLD hosts also reminisce about the team's 2023 predictions podcast to see if these guests could really see the future.
The Season 6 finale of the GOLD podcast has landed! Tune in to hear Isabel and Jade present a discussion with Kinnari Patel, President and Chief Operating Officer, Rocket Pharmaceuticals.
In this episode, Kinnari shares her thoughts on how the industry can engage the next generation of scientific leaders to propel itself into the future. Tune in to find out what might be stopping the younger generation from pursuing a career in pharma and how the industry can work to change their minds, the benefits of a more diverse workforce, the future of drug development and more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Mastering medical affairs
- Taking women to the top of pharma
- Do happy employees equal better innovation?
- Last week's podcast: A patient's right to thrive, not just survive
Tune in to the latest episode of the GOLD podcast which sees Isabel sit down for a chat with Wendy Bartie, Senior Vice President and General Manager, US Hematology and Cell Therapy, Bristol Myers Squibb.
In the episode, Wendy discusses her passion for developing life-saving cancer drugs with less toxic side effects. Learn about how far the industry has come, while being guided through the ways in which the sector could still evolve for the benefit of patients.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Going for gold in gynaecological cancers
- Mental health matters in pharma's approach to care
- Last week's podcast: What motivates and challenges GOLD's guests?
Tune in for a sneak peek of GOLD's latest Catalyst interview with Dr Peter Ahnesorg, Global Hematology Franchise Head, Roche. In this exclusive teaser of the full interview, Peter talks about why he left research for industry, Roche's commitment to ensuring equitable access to its medicines and what he believes are the qualities of a good leader today. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: * Podcast: Changing the tide on health inequities * Podcast: Do happy employees equal better innovation? * Last week’s podcast: A high-speed chase for oncology innovation
Tune in to the latest episode of the GOLD podcast as Isabel and Jade present a discussion with Jaime Manzanera Gómez, EMEA Brand Director, Oncology, Eisai, who details how oncology teams can best increase the pace of innovation in the field.
In this episode, Jaime shares his thoughts on the pace of innovation after the heights of COVID-19, how regulatory constraints can sometimes affect the industry's thirst for innovation, his passion for the outdoors and much more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Do happy employees equal better innovation?
- Going for gold in gynaecological cancers
- Last week's podcast: Changing the tide on health inequities
Listen in to the newest episode of the GOLD podcast, in which Jade digs deep into the diversity, equity and inclusion (DE&I) space with Marion Brooks, Vice President and US Country Head, Diversity, Equality and Inclusion, Novartis.
In the interview, the pair discuss why Marion left a career in commercial for DE&I, the need for more action on health inequities, Novartis's approach to creating a more diverse medical workforce and much more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Roche's Davidek Herron: My journey with diversity, equity and inclusion
- 4 top tips to create the perfect ERG
- Last week's podcast: Why HCPs are losing trust in pharma marketing
Tune in to a new episode of the GOLD podcast as hosts Isabel and Jade discuss a timely topic for the pharmaceutical industry: how to build trust with healthcare professionals.
With a recent survey showing that 80% of HCPs don't trust the content the industry produces for them, the team look at the story behind the statistic. They explore where the problems lie and how the industry can improve for the benefit of its customers.
GOLD also hears from Rob Verheul, CEO, Graphite Digital, the company behind the report, who shares his takeaways from the research. These include the importance of data accuracy, the value of a good customer experience, top tips for building trust and more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Conquering generational differences in HCP marketing
- Meeting customer needs in medical affairs
- Getting to grips with customer experience
Tune in to the latest instalment of the GOLD podcast, which sees Isabel and Jade present a conversation with Rick Hollis, Director of Business Excellence, Ipsen, about his views on how the pharmaceutical industry's customer engagement model needs to grow and evolve.
Discover the highs and lows of creating meaningful marketing interactions with this week's guest as Rick explores the evolution of customer engagement, his top tips for creating more enticing communications, his vision for a customer experience utopia and more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Upgrading the personal touch in CX
- Getting to grips with customer engagement
- Last week’s podcast: Investigating the reality of rare disease research
Discover the reality behind the expectations of rare disease research and drug development with Isabel and Jade as they present a discussion with Dr Ian Winburn, Vice President, Global Lead for Rare Hematology, Pfizer. Tune in to hear Ian and Isabel discuss the current pharmaceutical landscape for rare diseases, including discussions around clinical trials, partnering early in the drug lifecycle, what the industry should be keeping in mind for the future of the field and much more. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: * Mitigating the rare disease RWD deficit * Last week’s podcast: Do happy employees equal better innovation
Tune in to the latest episode of the GOLD podcast as Nate Cope, Chief Operating Officer, Otsuka Europe, details how companies can drive innovation by being a great place to work.
In this episode, Nate reveals the story behind his passion for prioritising people, what companies should and shouldn't do in their mission to become more people-centric and an example of how Otsuka sought to reward its employees for getting better sleep.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- 4 top tips to create the perfect ERG
- The driving seat of organisational change
- Last week's podcast: Taking the pulse of digital health
The GOLD podcast is back on the airwaves! Join Isabel and Jade every Tuesday as they speak to a new bunch of inspiring leaders from the pharmaceutical industry. The first interviewee of the season is Parveen Jayia, Therapy Area Head, Breast and Gynaecological Cancers, AstraZeneca, who talks to GOLD about the role digital health can play in the future of the industry. From working with policymakers to designing the perfect digital health strategy, tune in to hear her top tips for staying ahead of the curve. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- AI, ChatGPT and modernising medical affairs
- Inspiring innovation and the future of digital therapeutics
- Going for gold in gynaecological cancers
The opinions and views expressed here are her personal and do not necessarily reflect the opinions or views of AstraZeneca or any subsidiary thereof.
In this final GOLD Nugget of the series, Jade reflects on her conversation with season finale guest Christy Seigel, General Manager, Breast and Women's Cancers Portfolio, Novartis US Oncology, from her episode ‘Going the extra mile for patients with disabilities’.
In this episode, Jade picks out her favourite anecdote Christy shared, which was how her experience of raising children with disabilities helped her to push for better disability inclusion within the pharmaceutical industry.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Christy’s full episode: Season finale: Going the extra mile for patients with disabilities - GOLD (emg-gold.com)
- Going for gold in gynaecological cancers
It is time for the third ‘GOLD nugget’ from Season 5, and Jade is highlighting her favourite insight shared by Sarah Jarvis, Global Lead for the Medical Consulting Practice, ZS, from her episode with colleague Sunil John, ‘Meeting customer needs in medical affairs’.
In this clip, Sarah shares findings from ZS's latest Medical Affairs Outlook report and details what medical education healthcare professionals want from the industry at each phase of the product lifecycle.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Sarah’s full episode: https://www.emg-gold.com/post/meeting-customer-needs-in-medical-affairs
- Revealing the true value of medical affairs: https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs
In the second episode of GOLD nuggets, Isabel looks back at her conversation with Dr Sunil Verma, Global Head of Oncology, Medical, AstraZeneca, in which the two discussed the journey to transforming cancer care.
In this particular clip, Sunil delves into what motivates him to wake up in the morning and what industry challenge can keep him awake at night.
Additional resources
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Sunil’s full episode: What will it take to transform cancer care? - GOLD (emg-gold.com)Mapping a path to personalised medicine
- Mapping a path to personalised medicine - GOLD (emg-gold.com)
As the GOLD team prepare for the next season of the podcast, take a walk down memory lane with Isabel and Jade as they share their GOLD Nuggets from Season 5.
In the first of these special bonus episodes, Isabel looks back at the very first episode of Season 5, featuring Philippe Kirby, Global Head of Channel Engagement and Execution, MSD. Isabel pulls out her favourite insight Philippe shared: how pharma teams can best gather information from HCPs to improve their customer experience.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: * Philippe’s full episode: Getting to grips with customer engagement * Upgrading the personal touch in CX
To bring season 5 of the GOLD podcast to a close, join Jade as she sits down with Christy Seigel, General Manager, Breast and Women’s Cancers Portfolio, Novartis US Oncology, to discuss the importance of disability inclusion in the pharmaceutical industry.
In this episode, Jade and Christy unpick her transition from general medicine to women’s cancer, how companies can best extend oncology care to those with disabilities, ways to expand diversity, equity and inclusion schemes to better support those living with disabilities and more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Going for gold in gynaecological cancers: https://www.emg-gold.com/post/going-for-gold-in-gynaecological-cancers
-
4 top tips to create the perfect ERG: https://www.emg-gold.com/post/4-top-tips-to-create-the-perfect-employee-resource-group
- Translating policy into action: https://www.emg-gold.com/post/translating-policy-into-action
- Last week’s episode: https://www.emg-gold.com/post/season-5-highlights-gold-medal-moments
As Season 5 of the GOLD podcast approaches its end, join Isabel and Jade as they share some of the most memorable moments from the last couple of months.
Join our hosts for a trip down memory lane as they look back on their ‘GOLD Medal Moments’ in the penultimate episode of the season. They cover topics such as the importance of avoiding tokenism, the value of personalisation, investing in customer experience and much more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- My journey with diversity, equity and inclusion https://www.emg-gold.com/post/my-journey-with-diversity-equity-and-inclusion
- Cell and gene therapy: a victim of its own success https://www.emg-gold.com/post/cell-and-gene-therapy-a-victim-of-its-own-success
- Mapping a path to personalised medicine https://www.emg-gold.com/post/mapping-a-path-to-personalised-medicine
-
Conquering generational differences in HCP marketing https://www.emg-gold.com/post/conquering-generational-differences-in-hcp-marketing
- Upgrading the personal touch in CX https://www.emg-gold.com/post/upgrading-the-personal-touch-in-cx
Uncover the latest customer expectations of medical affairs in this episode of the GOLD podcast, which sees the team speak with not one but two MA leaders from top healthcare consultancy firm, ZS. Join guests Sarah Jarvis, Global Lead for the Medical Consulting Practice, and Sunil John, Principal and Co-Lead Global Medical Affairs Practice, as they delve into ZS's latest medical affairs outlook report. Find out what customers want from omnichannel, lifecycle medical education preferences and so much more. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: * Revealing the true value of medical affairs * 5 ways pharma can ensure omnichannel success * The ZS medical outlook report 2023 * Last week’s episode: Translating policy into action
Explore how the pharmaceutical industry can turn diversity, equality and inclusion initiatives into transformational change in the latest episode of the GOLD podcast, where Jade Williams talks to Anita Ralli, Director, Government Affairs, Inclusion and Diversity, Employee Resource Group Lead, Gilead Sciences UK.
In this episode, Jade picks the brains of our guest to find out how companies can attract diverse talent to their workforce, key ways to create an environment where employees can be themselves and how to ensure Employee Resource Groups are successful.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Podcast: Pharma, Pride and the LGBTQ+ community
Podcast: International Women's Day 2023 special
My journey with diversity, equity and inclusion - Davidek Herron
4 top tips to create the perfect employee resource group
Last week's episode: Meet GOLD’s new catalyst – CSL Behring’s Karen Pinachyan
In this week’s episode, Isabel and Jade share some snippets from the interview with GOLD’s next catalyst Karen Pinachyan, Head of Medical Affairs, Europe, CSL Behring. In this teaser edition of the full interview, Karen shares his motivation for joining the pharmaceutical industry, his thoughts on how to shift the care paradigm towards personalised medicine and how he believes both industry and healthcare systems can work together to deliver more value to patients. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: * Mapping a path to personalised medicine * Revealing the true value of medical affairs * Podcast: Is medical affairs the Ferrari of the pharma industry? * Last week’s episode: Shaping success in cell therapy
As the US celebrates the 4th of July today, navigate the evolving landscape of cell therapy with hosts Isabel and Jade as they present an insightful discussion with Warner Biddle, Senior Vice President and Global Head of Commercial, Kite, a Gilead Company. Tune in to hear Warner discuss why creating equitable patient access is a ‘team sport’, the potential barriers to advancing cell therapy and what he would choose as his TED Talk topic. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: * Cell and gene therapy: a victim of its own success https://www.emg-gold.com/post/cell-and-gene-therapy-a-victim-of-its-own-success * Mapping a path to personalised medicine https://www.emg-gold.com/post/mapping-a-path-to-personalised-medicine * Podcast: Driving access to all medicines https://www.emg-gold.com/post/driving-access-to-all-medicines * Last week’s episode: Pharma, Pride and the LGBTQ+ community https://www.emg-gold.com/post/pharma-pride-and-the-lgbtq-community
This week, as we approach the end of Pride Month, the GOLD team looks into how the industry can proactively support patients and staff who are part of the LGBTQ+ community. Join Isabel and Jade as they look at how the industry can avoid 'rainbow washing' and tokenism to drive a positive change both inside and outside their organisations. This will include highlighting effective initiatives from BMS, GSK, Genetech and Pfizer, who like many others, are committed to supporting the community during Pride Month and beyond. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: * Confronting health inequities for transgender patients * Reverse mentoring: a how-to guide * 4 top tips to create the perfect ERG * Last week's episode: What will it take to transform cancer care?
Explore the industry's evolving mission to advance cancer research and care in this new episode of the GOLD podcast with hosts Isabel and Jade, featuring an insightful conversation with Dr Sunil Verma, Global Head of Oncology, Medical, AstraZeneca. In this episode, Isabel uncovers Sunil's passion for working in oncology, his analysis of where cancer care has been and where it is going, why personalised medicine is the ultimate goal for oncology and an insight into the challenge that can keep him up at night. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: * Mapping a path to personalised medicine * Christi Shaw on her drive to develop innovative cancer treatments * Mental health matters in pharma’s approach to care * Last week’s episode: Powering the new commercial model
Tune in to the next episode of the GOLD podcast to hear the team's latest conversation with a leading figure in the pharmaceutical industry. What is being discussed this week? The industry's evolving commercial model. In this week’s episode, Isabel chats with Chetak Buaria, Vice President of Global Commercial Operations, Oncology, Merck Group, about how a new model driven by technology and data is in sight. The two explore what this new model might look like, whether pharma is ready for it and how to move forward without alienating internal or external stakeholders. The opinions and views expressed here are his personal and do not necessarily reflect the opinions or views of Merck Healthcare KGaA, Germany or any subsidiary thereof. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: * Tipping the scales of KOL success * Conquering generational differences in HCP marketing * Is the pharma rep at death’s door? * Last week’s episode: Getting to grips with customer experience
Join Isabel and Jade in kicking off Season 5 of the GOLD podcast with this brand-new episode, which sees the pair return to the airwaves to share more brilliant insights from experts in the pharmaceutical industry. In this first episode, Isabel discusses customer experience with Philippe Kirby, Global Head of Channel Engagement and Execution, MSD. In the conversation, Philippe reveals what pharma is getting right and wrong, how to get valuable and actionable feedback from customers, how to balance customer experience and compliance and much more. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Upgrading the personal touch in CX
- Crafting customer experience
- 5 ways pharma can ensure omnichannel success
The GOLD team are delighted to announce that Season 5 of The GOLD Podcast is just around the corner. To mark the run up to the next series, Isabel and Jade take a moment in this episode to reminisce about some of the hot topics our brilliant guests shared with us in Season 4.
Join our hosts as they journey through their ‘GOLD medal moments’ from last season, covering topics such as the rise of AI, the importance of empathy in leadership, the fight for representation in organisations and more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Behind the hype of ChatGPT: https://www.emg-gold.com/post/behind-the-hype-of-chatgpt
Taking women to the top of pharma: https://www.emg-gold.com/post/taking-women-to-the-top-of-pharma
Raising women’s health up the agenda: https://www.emg-gold.com/post/raising-women-s-health-up-the-agenda
Medical affairs, AI and insight generation: https://www.emg-gold.com/post/medical-affairs-ai-and-insight-generation
To mark the final episode of Season 4, Isabel and Jade reminisce about their favourite moments from the series and give an exclusive teaser for the next issue of GOLD – out on 13 April. Expect discussion on topics such as the current state of life sciences innovation in the UK, the latest advances and potential of personalised medicine, a deep dive into our Catalyst interview with Christi Shaw, former CEO, Kite Pharma, and lots of bonus insights from the writers themselves. Be sure to subscribe here to receive the full issue straight to your inbox on publication day. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: * Pharma in the UK * Mapping a path to personalised medicine
In the penultimate episode of Season 4, the GOLD team are joined by Dr Zsuzsanna Devecseri, Vice President and Head of Global Oncology Medical, Sanofi Genzyme, to discuss her career journey and experience within the pharmaceutical industry. Isabel and Zsuzsanna explore a wide range of topics during their conversation, including diversity and inclusion, the importance climbing the ranks of leadership at the right pace, ensuring personalised medicines can reach patients in need and much more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Elevating pharma’s parental leave policies: https://www.emg-gold.com/post/elevating-pharma-s-parental-leave-policies
- Setting the stage for a more equitable future: https://www.emg-gold.com/post/setting-the-stage-for-a-more-equitable-future
- Driving access to all medicines: https://www.emg-gold.com/post/driving-access-to-all-medicines
- Diversity: from ideas to action: https://www.emg-gold.com/post/diversity-from-ideas-to-action
This week on the GOLD Podcast, Isabel and Jade present a conversation with Gaurav Sanganee, Managing Director and Principal Consultant, Closing Delta, about how pharmaceutical teams can make the most of a tight budget and leverage digital transformation for the benefit of customers and patients.
During their discussion, Jade and Gaurav delve into his transition from retail to pharma, explore how companies can make quick wins by leveraging modular content and omnichannel and how AI is facilitating the digital transformation of marketing strategies.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Upgrading the personal touch in CX https://www.emg-gold.com/post/upgrading-the-personal-touch-in-cx
- AI, ChatGPT and modernising medical affairs https://www.emg-gold.com/post/ai-chatgpt-and-modernising-medical-affairs
- Super reps, ChatGPT and pharma’s future on social media https://www.emg-gold.com/post/podcast-super-reps-chatgpt-and-pharma-s-future-on-social-media
This week on the GOLD podcast, Isabel is joined by Matt Lewis, Co-Founder of Inizio Medical Analytics and Innovation, to discuss the future of AI in the pharmaceutical industry and the potential uses of ChatGPT in medical affairs. In this episode, Matt explores the need to modernise medical affairs, top ways pharma teams could save time and resources with ChatGPT, the likelihood of AI one day becoming as commonplace as electricity and much more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Is medical affairs the Ferrari of the pharma industry?: https://www.emg-gold.com/post/podcast-is-medical-affairs-the-ferrari-of-the-pharma-industry
- Medical affairs, AI and insight generation: https://www.emg-gold.com/post/medical-affairs-ai-and-insight-generation
- Super reps, ChatGPT and pharma’s future on social media: https://www.emg-gold.com/post/podcast-super-reps-chatgpt-and-pharma-s-future-on-social-media
- Revealing the true value of medical affairs: https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs
This week on the GOLD podcast, the team is joined by Claudia Martínez, Research Programme Manager, Generics and Diabetes Care, Access to Medicine Foundation, to discuss all things access within the pharmaceutical industry. In this episode, Claudia and Jade explore a range of topics, including the story behind her passion for access to medicine, the industry's progress in making medicines more widely available in low- and middle-income countries and the Foundation's latest focus on driving access to generic drugs.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Claudia’s first GOLD Podcast: https://www.emg-gold.com/post/podcast-talking-to-claudia-martinez
Pharma in Kenya: https://www.emg-gold.com/post/pharma-in-kenya
Pharma in India: https://www.emg-gold.com/post/pharma-in-india
This week, the GOLD team is delighted to bring you a special International Women's Day (IWD) podcast featuring Pallavi Bansal, Associate Vice President of Oncology, Genitourinary Cancers and Haematology, Merck, and Emma Chaffin, Vice President, Country Head and Site Lead, Galapagos. The two women reflect on this year's IWD theme, #EmbracingEquity, why female representation in pharma is so important and how leaders can foster a sense of belonging within their organisations. Isabel and Jade also discuss the latest GOLD content on female representation and equality in pharma.
Additional resources:
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Infographic: Attracting more diverse talent into STEM https://www.emg-gold.com/_files/ugd/b8a9db_153874fc1b484455a9d2840f3118317c.pdf
- Elevating pharma’s parental leave policies: https://www.emg-gold.com/post/elevating-pharma-s-parental-leave-policies
- Reverse mentoring: a how-to guide: https://www.emg-gold.com/post/reverse-mentoring-a-how-to-guide
- Setting the stage for a more equitable future: https://www.emg-gold.com/post/setting-the-stage-for-a-more-equitable-future
- HBA Gender Parity Collaborative https://genderparity.hbanet.org/
This week, Isabel catches up with GOLD’s long-time friend Bora Erdemli, Associate Principal and Leader of Medical Affairs Practice, Europe, ZS. She asks Bora to break down the value of the medical affairs function, asking whether it is being properly utilised by pharma organisations. Bora also shares his thoughts on the future of the MSL, what skills new recruits will need to succeed and his top predictions for the next five years in MA.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Revealing the true value of medical affairs https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs
- Mastering medical affairs https://www.emg-gold.com/post/mastering-medical-affairs
- Darshan Kulkarni on Super reps, ChatGPT and pharma’s future on social media https://www.emg-gold.com/post/podcast-super-reps-chatgpt-and-pharma-s-future-on-social-media
This week, GOLD talks to Darshan Kulkarni, Principal Attorney, The Kulkarni Law Firm, which focuses on regulatory and compliance for life sciences, about key trends in medical affairs and marketing today. He discusses whether MSLs will one day replace sales reps, the role of ChatGPT in healthcare, pharma’s future on social media and much more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- The feature Darshan contributed to: Confronting health inequities for transgender patients https://www.emg-gold.com/post/confronting-health-inequities-for-transgender-patients
- A takeover, a tweet and trouble for pharma marketers https://www.emg-gold.com/post/a-takeover-a-tweet-trouble-for-pharma-marketers
- Preparing MSLs for the spotlight https://www.emg-gold.com/post/preparing-msls-for-the-spotlight
- Davidek Herron on 5 ways pharma can ensure omnichannel success https://www.emg-gold.com/post/5-ways-pharma-can-ensure-omnichannel-success-davidek-herron
- Mental health matters in pharma's approach to care https://www.emg-gold.com/post/mental-health-matters-in-pharma-s-approach-to-care
This week, the team shares a teaser of GOLD’s latest catalyst interview with Mina Makar, Senior Vice President, Global Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca. He talks to Isabel about why he decided to leave pharmacy for pharma, his passion for tackling unmet needs and championing the patient perspective as well as his thoughts on how to be an effective leader.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Catalyst interview: Mina Makar on tackling unmet patient needs https://www.emg-gold.com/post/mina-makar-on-tackling-unmet-patient-needs
Turning patient insights into action https://www.emg-gold.com/post/turning-patient-insights-into-action
Our last catalyst: John Wahba on the medical affairs evolution https://www.emg-gold.com/post/john-wahba-on-the-medical-affairs-evolution
The GOLD Podcast is back for Season 4, and it is returning with a bang as Helena speaks to Kavita Panke, Disease Area Strategy Leader, Neurodegeneration, Janssen. An inspiring pharma leader working in a rapidly evolving area of the industry, Kavita reveals the reasons behind her passion for neuroscience, how to build a high-performing team and her inspiring goals for 2023.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- The brains behind neurological breakthroughs
- The vast galaxy of neurology https://www.emg-gold.com/post/the-vast-galaxy-of-neurology
- The value of purpose https://www.emg-gold.com/post/the-value-of-purpose
- Claus Zieler on leadership https://www.emg-gold.com/post/claus-zieler-on-leadership
For our fourth and final GOLD Nugget of Season 3, Helena looks back to our Catalyst interview with Reshema Kemps-Polanco, Executive Vice President and US Head, Novartis Oncology, sharing some of Reshema's ideas for tackling clinical trial recruitment gaps, her personal take on Nelson Mandela’s approach to dealing with failure and why she believes equal representation matters in the pharma industry and beyond.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Reshema’s full episode: Meet GOLD's next catalyst – Reshema Kemps-Polanco https://www.emg-gold.com/post/podcast-meet-gold-s-next-catalyst-visionary-leader-reshema-kemps-polanco Catalyst interview: Reshema Kemps-Polanco on drive, diversity and finding time for family https://www.emg-gold.com/post/reshema-kemps-polanco-on-drive-diversity-and-finding-time-for-family Ripples of change in R&D https://www.emg-gold.com/post/ripples-of-change-in-research-and-development Setting the stage for a more equitable future https://www.emg-gold.com/post/setting-the-stage-for-a-more-equitable-future
Join Helena and Isabel in ringing in the new year with a special episode in which five of our previous guests share their predictions for what could lie ahead for the pharmaceutical industry in 2023. Together, they discuss a broad range of topics including greater implementation of digital health, social media’s impact on the space, new legislation and much more.
If you are interested in learning more about the topic areas discussed in this episode, check out the following content:
Looking forward to the future of pharma https://www.emg-gold.com/post/looking-forward-to-the-future-of-pharma-davidek-herron
Utilising data lakes in pharma https://www.emg-gold.com/post/utilising-data-lakes-in-pharma
Revealing the true value of medical affairs https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs
The changing rhythm of digital therapeutics https://www.emg-gold.com/post/the-changing-rhythm-of-digital-therapeutics
Find a handy list of our guests’ full episodes at https://www.emg-gold.com/post/podcast-the-2023-pharma-forecast
This GOLD Nugget episode sees Helena reflect on some of the best insights offered by Pav Rishiraj, Director and Head of Pharmacovigilance at Ipsen. She shares some of Pav's thoughts on how the often under-recognised field of pharmacovigilance has changed – particularly its rapid evolution during the COVID-19 pandemic – and its importance as a strategic enabler, as well as Pav's advice on what pharma should do to ensure teams feel valued and integral to the businesses they serve.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Pav’s full episode: Pharmacovigilance past, present and future https://www.emg-gold.com/post/podcast-pharmacovigilance-past-present-and-future
The physics of pharmacovigilance https://www.emg-gold.com/post/the-physics-of-pharmacovigilance
In the second of four special bonus episodes, Helena looks back at GOLD’s conversation with Paul Simms, CEO, Impatient Health. She considers some of the gold nuggets that Paul shared, including insights on the current state of pharma’s reputation and the ways in which pharma can recover and bolster its reputation.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Paul’s full episode: Unpicking pharma’s reputation in pop culture https://www.emg-gold.com/post/podcast-unpicking-pharma-s-reputation-in-pop-culture
Reframing Pharma’s bad boy reputation https://www.emg-gold.com/post/reframing-pharma-s-bad-boy-reputation
Hear more from Paul:
Is the pharma rep at death's door? https://www.emg-gold.com/post/is-the-pharma-rep-at-death-s-door
The reality of the metaverse https://www.emg-gold.com/post/the-reality-of-the-metaverse
In the first of four special bonus episodes, Helena looks back at the launch episode of Season 3, which featured Dr Juby Jacob-Nara, Vice President and Global Medical Head for Respiratory, Allergy and Gastro-Intestinal Diseases, Sanofi. Helena considers some of the gold nuggets that Juby shared, including insights on the importance of cross-functional experience, team diversity and continual learning.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Juby’s full episode: Meet GOLD’s new catalyst – medical aficionado Juby Jacob-Nara https://www.emg-gold.com/post/podcast-meet-gold-s-new-catalyst-medical-aficionado-juby-jacob-nara
Catalyst interview: Juby Jacob-Nara on medical affairs https://www.emg-gold.com/post/juby-jacob-nara-on-medical-affairs
Revealing the true value of medical affairs https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs
Preparing MSLs for the spotlight https://www.emg-gold.com/post/preparing-msls-for-the-spotlight
This week’s season finale episode welcomes back some friends of the podcast – most of whom we interviewed on the show this year – to reflect on the past 12 months and give us their take on their key highlights. Hear Aliya Omer, Claire Gillis, Robert Grimm, Michele Manto, Paul Simms and Wendy White, unravel the past year in pharma, looking at everything from access challenges to organisational change to huge wins for marketing approaches and sharing some fascinating insights.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
The impact of global instability https://www.emg-gold.com/_files/ugd/b8a9db_a8c25d06ae954bb98e0fa3448f259168.pdf
Behind the headlines of the Inflation Reduction Act https://www.emg-gold.com/post/behind-the-headlines-of-the-inflation-reduction-act
Revealing the true value of medical affairs https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs
Embracing pharma's digital transformation https://www.emg-gold.com/post/embracing-pharma-s-digital-transformation
Elevating pharma’s parental leave policies https://www.emg-gold.com/post/elevating-pharma-s-parental-leave-policies
This week on the podcast, GOLD discusses the field of pharma sales with James Harper, Founder and Managing Director, twentyeightb. James shares his story of joining the pharma industry, the incredible importance of striving to add value to every customer engagement, whether MSLs and sales reps could ever converge and the priority of mindset over toolset. All this stems from the inaugural event from James’ new initiative ‘Digital Pharma: Unlocked’ – a group aiming to help the pharma industry see digital as a positive enablement tool.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Is the pharma rep at death's door? https://www.emg-gold.com/post/is-the-pharma-rep-at-death-s-door
Revealing the true value of medical affairs https://www.emg-gold.com/post/revealing-the-true-value-of-medical-affairs
A Field Force for the Future https://www.emg-gold.com/post/a-field-force-for-the-future
Alexander Natz on pricing and access https://www.emg-gold.com/post/podcast-pharma-in-south-africa-access-pricing-and-reimbursement
In this week’s episode, Helena and Isabel share an interview with GOLD’s new catalyst John Wahba, Medical Head of the Global Digital Hub, GSK. In this teaser edition of the catalyst interview, John shares his motivations for joining the pharmaceutical industry, key takeaways from his time in the medical field, thoughts on digitally optimising MSL teams and much more. If you want to read the written interview in full, check out the link below.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- John Wahba on the medical affairs evolution
- Pharma in Japan
- Urgent need to boost trade for UK's life sciences, says ABPI
This week, the GOLD team presents a special episode to mark World AIDS Day, which is taking place on 1st December. Hear from Dr Nneka Nwokolo, Global Head of Patient Affairs, ViiV Healthcare, and Claire Gillis, CEO, VMLY&R Health, as they both discuss HIV stigma, prevention and care in the world today and how pharma can support healthcare professionals and patients. GOLD also speaks to former guest, Laurence Woollard, Director, On the Pulse Consultancy, and haemophilia patient advocate, to get his verdict on the new approval of a first-of-its-kind gene therapy for haemophilia B.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Access win for HIV patients in sub-Saharan Africa https://www.emg-gold.com/post/access-win-for-hiv-patients-in-sub-saharan-africa
- Monkeypox, misinformation and mitigating a pandemic https://www.emg-gold.com/post/monkeypox-misinformation-and-mitigating-a-pandemic
- Building campaigns with communities https://www.emg-gold.com/post/building-campaigns-with-communities
- Laurence Woollard on challenges facing the haemophilia community https://www.emg-gold.com/post/podcast-digital-solutions-cell-and-gene-therapy-and-haemophilia-in-focus
This week, GOLD chats to Silvia Taylor, Executive Vice President and Chief Communications Officer, Novavax. She reveals what it was like to join Novavax at the height of the pandemic, the importance of storytelling to ensure uptake and access to new vaccines and the advice she would give her younger self on how to succeed. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Pharma's sustainability agenda centre stage in new ABPI report https://www.emg-gold.com/post/pharma-s-sustainability-agenda-centre-stage-in-new-abpi-report
- 2022 Access to Medicine Index reveals improvement https://www.emg-gold.com/post/2022-access-to-medicine-index-reveals-improvement
- Keeping the spark alive in vaccine development https://www.emg-gold.com/post/keeping-the-spark-alive-in-vaccine-development
- How to enhance value and access across pharma https://www.emg-gold.com/post/podcast-how-to-enhance-value-and-access-across-pharma
This week, the GOLD team shares a conversation with Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson. He discusses his lengthy career within value and access and his drive to enter the industry, his proudest achievements while working at J&J and the importance of having a good leader to learn from. And in news you might have missed, the team showcases some recent investment in the psychedelics market, a first-in-10-years paediatric vaccine and a new study investigating the prevalence of undiagnosed CKD.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Behind the headlines of the inflation reduction act https://www.emg-gold.com/post/behind-the-headlines-of-the-inflation-reduction-act
Pharma in South Africa, access, pricing and reimbursement https://www.emg-gold.com/post/podcast-pharma-in-south-africa-access-pricing-and-reimbursement
Margo Warren on global access to medicine https://www.emg-gold.com/post/podcast-margo-warren-on-global-access-to-medicine
In this week’s episode, GOLD speaks to Eugene Borukhovich, Co-Founder and COO, YourCoach.Health, about the evolving landscape of digital therapeutics. He discusses his journey into the pharmaceutical space, tips for companies looking to get into DTx and his predictions for this tech evolution over coming years. And news you might have missed showcases collaborative efforts against ebola and good news from Gilead Sciences.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
The changing rhythm of digital therapeutics https://www.emg-gold.com/post/the-changing-rhythm-of-digital-therapeutics
Embracing pharma’s digital transformation https://www.emg-gold.com/post/embracing-pharma-s-digital-transformation
Top tips for digital innovation and the future of patient centricity https://www.emg-gold.com/post/podcast-top-tips-for-digital-innovation-and-the-future-of-patient-centricity
This week, the GOLD team discusses key articles and themes from the latest magazine, drilling down into topics such as what pharma can learn from the tech giants, the industry’s response to Roe v. Wade and the delicate balance of biotech success, to give listeners some exclusive context and insights on three fascinating stories affecting the industry today.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Following in the footsteps of tech giants https://www.emg-gold.com/post/following-in-the-footsteps-of-tech-giants
Pharma’s response to Roe v. Wade https://www.emg-gold.com/post/pharma-s-response-to-roe-v-wade
Is the biotech boom on thin ice? https://www.emg-gold.com/post/is-the-biotech-boom-on-thin-ice
Decentralised clinical trials: going green https://www.emg-gold.com/post/decentralised-clinical-trials-going-green
In this week’s episode, GOLD speaks to Patrick Short, CEO, Sano Genetics, about the challenges and opportunities in genetic medicine today. He discusses his personal connection to tackling genetic diseases, the top reasons behind research participation hesitancy and the therapy areas in which he believes genomic testing and medicine could be most impactful. Plus, news from the World Health Summit.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Tackling the trust gap in genomic medicine https://www.emg-gold.com/post/tackling-the-trust-gap-in-genomic-medicine
- The rare disease disparity https://www.emg-gold.com/post/the-rare-disease-disparity
- Davidek Herron on embracing pharma's digital transformation https://www.emg-gold.com/post/embracing-pharma-s-digital-transformation
In this week’s episode, Helena and Isabel share an interview with GOLD’s next Catalyst Reshema Kemps-Polanco, Executive Vice President and US Head, Novartis Oncology. In this special extended version of the interview exclusive to the podcast, hear Reshema’s story and insights in full, including the life experiences that have led her to where she is today, her ideas for tackling clinical trial recruitment gaps, why equal representation matters and so much more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
-
Ripples of change in R&D https://www.emg-gold.com/post/ripples-of-change-in-research-and-development
-
Setting the stage for a more equitable future https://www.emg-gold.com/post/setting-the-stage-for-a-more-equitable-future
- Previous Catalyst interview with Juby Jacob-Nara https://www.emg-gold.com/post/juby-jacob-nara-on-medical-affairs
In this week’s episode, Helena is joined by Paul Simms, CEO of Impatient Health, to delve deeper into GOLD’s recent cover feature on reframing pharma’s bad boy reputation. They chat about the current state of pharma’s reputation and the influence of the media and pop culture on this, the ways in which pharma can recover and bolster its reputation, and more. And in ‘news you might have missed’, Helena discusses the latest global awareness campaign from Leo Pharma, the ABPI’s recent survey on pharma and academia collaboration and a new Marvel comic strip features Pfizer’s COVID-19 vaccination efforts in the US.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Reframing pharma's bad boy reputation https://www.emg-gold.com/post/reframing-pharma-s-bad-boy-reputation
Talking to Paul Simms https://www.emg-gold.com/post/podcast-talking-to-paul-simms
In this week's episode Helena and Isabel were honoured to be joined by Rino Rappuoli, Head of External R&D and Chief Scientist at GSK Vaccines. He discusses his career inspiration and journey; his work on novel scientific concepts such as reverse vaccinology, which modern vaccines are based on; and his interest in meningitis, as well as the lasting impact of COVID-19 on the vaccine landscape, how he sees the field developing in future and what investment and innovation is needed from pharma to achieve his vision.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Keeping the spark alive in vaccine development https://www.emg-gold.com/post/keeping-the-spark-alive-in-vaccine-development
GSK's Judy Stewart on vaccines https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases
The return of the vaccines https://www.emg-gold.com/post/the-return-of-the-vaccines
Is mRNA the future of vaccine technology? https://www.emg-gold.com/_files/ugd/b8a9db_63ca75dce7a64cd39b356ac1ffb18358.pdf
[Yesterday 15:46] Helena Beer
Top tips for digital innovation and the future of patient centricity
In this week’s episode of The GOLD Podcast, Helena is joined by Konrad Dobschuetz, National Director at NHS Innovation Accelerator and Chief Enterprise Officer at UCL Partners, who discusses all things digital innovation. They chat about his transition from the fashion industry to pharma, some digital innovation top tips for companies and his new role at the NHS and the importance of collaboration, plus his take on how the humble automobile may someday turn into a diagnostic tool. And in ‘news you might have missed’, Helena discusses the latest from Boehringer Ingelheim, Sanofi and GSK.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Meet GOLD's catalyst - digital innovator, Davidek Herron: https://www.emg-gold.com/post/podcast-catalyst-digital-innovator-davidek-herron
Digitalisation: moving past paperless: https://www.emg-gold.com/post/digitalisation-moving-past-paperless
Reframing pharma's bad boy reputation https://www.emg-gold.com/post/reframing-pharma-s-bad-boy-reputation
Taking a bet on blockchain https://www.emg-gold.com/post/taking-a-bet-on-blockchain
[Yesterday 15:46] Helena Beer
Top tips for digital innovation and the future of patient centricity
In this week’s episode of The GOLD Podcast, Helena is joined by Konrad Dobschuetz, National Director at NHS Innovation Accelerator and Chief Enterprise Officer at UCL Partners, who discusses all things digital innovation. They chat about his transition from the fashion industry to pharma, some digital innovation top tips for companies and his new role at the NHS and the importance of collaboration, plus his take on how the humble automobile may someday turn into a diagnostic tool. And in ‘news you might have missed’, Helena discusses the latest from Boehringer Ingelheim, Sanofi and GSK.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Meet GOLD's catalyst - digital innovator, Davidek Herron: https://www.emg-gold.com/post/podcast-catalyst-digital-innovator-davidek-herron
Digitalisation: moving past paperless: https://www.emg-gold.com/post/digitalisation-moving-past-paperless
Reframing pharma's bad boy reputation https://www.emg-gold.com/post/reframing-pharma-s-bad-boy-reputation
Taking a bet on blockchain https://www.emg-gold.com/post/taking-a-bet-on-blockchain
This week’s episode features a fascinating conversation with Samin Saeed, UK Chief Scientific Officer and Medical Director at Novartis UK. She discusses a whole host of medical affairs-related issues, including the transition from medicine to pharma, cross-functionality, commercial versus medical affairs, and lots more besides, including a fascinating discussion about leadership, company culture and soft skills development. And ‘news you might have missed’ focuses on the European life sciences gender pay gap and new investment for Novartis.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Preparing MSLs for the spotlight https://www.emg-gold.com/post/preparing-msls-for-the-spotlight
Juby Jacob-Nara on medical affairs https://www.emg-gold.com/post/juby-jacob-nara-on-medical-affairs
Aliya Omer on gender equality https://www.emg-gold.com/post/podcast-aliya-omer-on-gender-equality
Reframing pharma’s bad boy reputation https://www.emg-gold.com/post/reframing-pharma-s-bad-boy-reputation
Elevating pharma’s parental leave policies https://www.emg-gold.com/post/elevating-pharma-s-parental-leave-policies
This week’s episode features a fascinating conversation with Samin Saeed, UK Chief Scientific Officer and Medical Director at Novartis UK. She discusses a whole host of medical affairs-related issues, including the transition from medicine to pharma, cross-functionality, commercial versus medical affairs, and lots more besides, including a fascinating discussion about leadership, company culture and soft skills development. And ‘news you might have missed’ focuses on the European life sciences gender pay gap and new investment for Novartis.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Preparing MSLs for the spotlight https://www.emg-gold.com/post/preparing-msls-for-the-spotlight
Juby Jacob-Nara on medical affairs https://www.emg-gold.com/post/juby-jacob-nara-on-medical-affairs
Aliya Omer on gender equality https://www.emg-gold.com/post/podcast-aliya-omer-on-gender-equality
Reframing pharma’s bad boy reputation https://www.emg-gold.com/post/reframing-pharma-s-bad-boy-reputation
Elevating pharma’s parental leave policies https://www.emg-gold.com/post/elevating-pharma-s-parental-leave-policies
This week, Marc and Helena are joined in the podcast studio by Pav Rishiraj, Director and Head of Pharmacovigilance at Ipsen, to shed some light on this often-overlooked field of pharma. He discusses his career journey in pharmacovigilance and how, in his experience, the field has changed; the importance of pharmacovigilance as a strategic enabler within businesses; and the outlook for the future of the field in terms of AI and automation. Helena also leads a short tribute to Her Majesty Queen Elizabeth II.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
The physics of pharmacovigilance https://www.emg-gold.com/post/the-physics-of-pharmacovigilance
RWE, the metrics of medical affairs and TikTok marketing https://www.emg-gold.com/post/podcast-real-world-evidence-the-metrics-of-medical-affairs-and-tiktok-marketing
This week, Marc and Helena are joined in the podcast studio by Pav Rishiraj, Director and Head of Pharmacovigilance at Ipsen, to shed some light on this often-overlooked field of pharma. He discusses his career journey in pharmacovigilance and how, in his experience, the field has changed; the importance of pharmacovigilance as a strategic enabler within businesses; and the outlook for the future of the field in terms of AI and automation. Helena also leads a short tribute to Her Majesty Queen Elizabeth II.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
The physics of pharmacovigilance https://www.emg-gold.com/post/the-physics-of-pharmacovigilance
RWE, the metrics of medical affairs and TikTok marketing https://www.emg-gold.com/post/podcast-real-world-evidence-the-metrics-of-medical-affairs-and-tiktok-marketing
It's good to be back! To celebrate the launch of Season 3 of The GOLD Podcast, Marc and Helena bring you a special extended version of our conversation with GOLD’s latest catalyst interviewee Dr Juby Jacob-Nara, Vice President and Global Medical Head for Respiratory, Allergy and Gastro-Intestinal Diseases, Sanofi. She speaks to Assistant Editor Isabel O’Brien about her move from medicine to medical affairs, her passion for cross-functional learning and how former physicians can empower themselves to succeed in the pharmaceutical industry.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Dr Juby Jacob-Nara on making it medical affairs https://www.emg-gold.com/post/juby-jacob-nara-on-medical-affairs
Preparing MSLs for the spotlight https://www.emg-gold.com/post/preparing-msls-for-the-spotlight
Luca Dezzani and Luisa Luciani-Silverman on medical affairs https://www.emg-gold.com/post/podcast-luca-dezzani-and-luisa-luciani-silverman-on-medical-affairs
Medical affairs evolution and the future for MSLs https://www.emg-gold.com/post/podcast-medical-affairs-evolution-and-the-future-for-msls
RWE, the metrics of medical affairs and TikTok marketing https://www.emg-gold.com/post/podcast-real-world-evidence-the-metrics-of-medical-affairs-and-tiktok-marketing
For our fifth and final GOLD Nugget of season 2, Helena looks back to one of our most popular episodes featuring Davidek Herron, Global Head of Digital at Roche. In these snippets, Davidek gives some great insights into what digital transformation means to him, drawing upon his time playing professional basketball in New York to illustrate his move into the pharma industry and some tips on learning from failure.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Davidek’s full episode: https://www.emg-gold.com/post/podcast-catalyst-digital-innovator-davidek-herron
Davidek Herron on digital transformation: https://www.emg-gold.com/post/davidek-herron-on-digital-transformation
Bridging the digital health divide: https://www.emg-gold.com/post/bridging-the-digital-health-divide
For our fifth and final GOLD Nugget of season 2, Helena looks back to one of our most popular episodes featuring Davidek Herron, Global Head of Digital at Roche. In these snippets, Davidek gives some great insights into what digital transformation means to him, drawing upon his time playing professional basketball in New York to illustrate his move into the pharma industry and some tips on learning from failure.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Davidek’s full episode: https://www.emg-gold.com/post/podcast-catalyst-digital-innovator-davidek-herron
Davidek Herron on digital transformation: https://www.emg-gold.com/post/davidek-herron-on-digital-transformation
Bridging the digital health divide: https://www.emg-gold.com/post/bridging-the-digital-health-divide
In this GOLD nugget, Helena looks back at thoughts shared by Aliya Omer, Vice President and Head of Global Portfolio and Program Strategy at Kite Pharma from our special International Women’s Day episode. Aliya reflects on her time playing basketball in her youth and fighting for gender equality both on and off the court, some key role models in her life and the importance of listening to engage rather than to reply.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Aliya’s full episode: https://www.emg-gold.com/post/podcast-international-womens-day-special
Bayer in top spot for equality, diversity and inclusion: https://www.emg-gold.com/post/bayer-in-top-spot-for-equality-diversity-and-inclusion
Setting the stage for a more equitable future: https://www.emg-gold.com/post/setting-the-stage-for-a-more-equitable-future
Diversity: from ideas to action: https://www.emg-gold.com/post/diversity-from-ideas-to-action
This GOLD Nugget episode sees Helena reflect on some of the insights offered by Laurence Woollard, haemophilia patient advocate and Founder and Director of On The Pulse Consultancy. In these clips, Laurence shares his personal experience of living with haemophilia and his journey into patient advocacy, the knowledge gap between the pharmaceutical industry and patients living with rare diseases and more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Laurence’s full episode: https://www.emg-gold.com/post/podcast-digital-solutions-cell-and-gene-therapy-and-haemophilia-in-focus
The progress and pain points of patient centricity: https://www.emg-gold.com/post/the-progress-and-pain-points-of-patient-centricity
The rare disease disparity: https://www.emg-gold.com/post/the-rare-disease-disparity
BioMarin supports haemophilia documentary initiative https://www.emg-gold.com/post/biomarin-supports-haemophilia-documentary-initiative
Roche renews haemophilia pledge https://www.emg-gold.com/post/roche-renews-haemophilia-pledge
For this week’s GOLD nugget, Helena highlights not one but two of GOLD’s previous guests from the world of Medical Affairs: Luca Dezzani, Vice President, Oncology Medical Affairs, Johnson & Johnson, and Luisa Luciani-Silverman, US Medical Head of Immuno-Oncology, AstraZeneca. They explore the potential value that can come from collaborating with different industries and some tips for measuring the value of medical affairs – it’s not one to be missed!
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Luca’s full episode: https://www.emg-gold.com/post/podcast-medical-affairs-evolution-and-the-future-for-msls
Luisa’s full episode: https://www.emg-gold.com/post/podcast-real-world-evidence-the-metrics-of-medical-affairs-and-tiktok-marketing
The Leap from Medicine to Medical Affairs: https://www.emg-gold.com/post/the-leap-from-medicine-to-medical-affairs
The GOLD Podcast may be on a break, but Helena is still here to provide you with some great insights – or GOLD Nuggets, if you will – from key opinion leaders in the pharmaceutical industry. In this special episode, she looks back at the very first episode of Season 2 which featured Judy Stewart, Senior Vice President and Head of US Vaccines at GSK. Helena considers some of the gold nuggets that Judy shared, including insights on both the vaccine industry and her approach to leadership. If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: Judy's full podcast episode: https://www.emg-gold.com/post/vaccines-leadership-and-blockchain Judy's Catalyst interview https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases GSK warns against routine vaccine complacency https://www.emg-gold.com/post/gsk-warns-against-routine-vaccine-complacency Haleon demerger completed by GSK https://www.emg-gold.com/post/haleon-demerger-completed-by-gsk
As Helena and Marc wrap up this season, they’re joined by Mike Watson, Chief Executive Officer of Mevox – a company committed to bringing vaccine technology into the 21st century.
Mike discusses the importance of developing new measles, mumps and rubella (MMR) vaccines, Mevox’s success so far in achieving this ambition – reaching series B funding – and its future trajectory, how COVID-19 will impact the future of vaccine development, along with a whole host of other fascinating insights. As Helena’s favourite interview of Season 2, it’s not one to be missed!
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
The return of the vaccines https://www.emg-gold.com/post/the-return-of-the-vaccines
Routine vaccinations: road to recovery https://www.emg-gold.com/post/routine-vaccinations-road-to-recovery
A heyday for mRNA https://www.emg-gold.com/post/a-heyday-for-mrna
Moderna set to bring mRNA innovation to UK https://www.emg-gold.com/post/moderna-set-to-bring-mrna-innovation-to-uk
GSK warns against vaccine complacency https://www.emg-gold.com/post/gsk-warns-against-routine-vaccine-complacency
This week, Claire Gillis, CEO, VMLY&R Health joins Helena and Marc on the airwaves to discuss the health and pharma highlights from the recent Cannes Lions International Festival, including the power of technology, how to spend smart on campaigns and her top moment from the festival this year.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Talking to Claire Gillishttps://www.emg-gold.com/post/podcast-talking-to-claire-gillis
Innovative tech, pharma supply chains and more https://www.emg-gold.com/post/podcast-innovative-tech-pharma-supply-chains-and-more
Spoonful of technology https://www.emg-gold.com/post/spoonful-of-technology-5
Cardiovascular catalyst launched by Novartis https://www.emg-gold.com/post/cardiovascular-catalyst-launched-by-novartis
In an interview double bill, Helena and Marc are joined two fantastic guests from the worlds of pharma marketing and commercial affairs. Michele Manto, Chief Commercial Officer, Galapagos, shares his thoughts on the differences in leading a large pharma company and an agile biotech, amongst other exciting topics, while Robert Grimm, Digital Marketing and Transformation Manager, Novo Nordisk, talks all things marketing with insights into developing campaigns.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech
Time to turn to TikTok https://www.emg-gold.com/post/time-to-turn-to-tiktok
Bridging the digital health divide https://www.emg-gold.com/post/bridging-the-digital-health-divide
The driving seat of organisational change https://www.emg-gold.com/post/the-driving-seat-of-organisational-change
In this episode, GOLD is joined by recent catalyst interviewee Claus Zieler, President of Established Markets, Astellas, who discusses crisis management, the importance of leaders in shaping company culture, the innovation he is most excited about, and much more.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Claus Zieler on leadership https://www.emg-gold.com/post/claus-zieler-on-leadership
Reverse mentoring: a how-to guide https://www.emg-gold.com/post/reverse-mentoring-a-how-to-guide
Supporting patients in a war zone https://www.emg-gold.com/post/supporting-patients-in-a-war-zone
The hard sell of cell and gene therapies https://www.emg-gold.com/post/the-hard-sell-of-cell-and-gene-therapies
In this week’s episode, the GOLD team is joined by Luca Dezzani, Vice President, Oncology Medical Affairs, Johnson & Johnson. After first meeting Luca when he contributed to a GOLD article about the transition from medicine to medical affairs in 2021, we invited him to join us on the airwaves to delve further into his experience within the function, he discusses how the medical affairs function has evolved, the future of the MSL, his views on the metaverse and the power of cross-industry partnership.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- The leap from medicine to medical affairs https://www.emg-gold.com/post/the-leap-from-medicine-to-medical-affairs
-
The reality of the metaverse https://www.emg-gold.com/post/the-reality-of-the-metaverse
-
Driving access to digital, gene therapies and rare disease education https://www.emg-gold.com/post/podcast-digital-solutions-cell-and-gene-therapy-and-haemophilia-in-focus
- The progress and pain points of patient centricity https://www.emg-gold.com/post/the-progress-and-pain-points-of-patient-centricity
In this Men’s Health Week special, the GOLD team is joined by Peter Baker, Director, Global Action on Men's Health and Chumi Khurana, Global Head, Prostate Cancer Disease Area Stronghold, Janssen Oncology. The two guests reveal what they think are the most pressing issues within men’s health today, highlight the importance of awareness campaigns, and comment on the role pharma can play in encouraging men to engage with their health.
In this episode of the podcast, the GOLD team is joined by Eric Bouilloux, Chief Development Officer, Istesso. Helena and Eric discuss his impressive career within the pharmaceutical space, drill down into the potential of immunometabolism in diseases like multiple sclerosis, highlight some tips and tricks for progressing within a chosen career path and review his predictions from his first interview with GOLD in 2019.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Talking to Eric Bouilloux https://www.emg-gold.com/post/podcast-talking-to-eric-bouilloux
Vaccines, leadership and blockchain https://www.emg-gold.com/post/podcast-vaccines-leadership-and-blockchain
"We’ve lost the focus that we had on routine vaccination of preventable diseases" https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases
In this episode, the GOLD team is joined by Natalie Yeadon, Co-Founder and CEO, Impetus Digital, to delve deeper into our recent feature, ‘Getting into gamification’, Content and Editorial Assistant Jade Williams talks to Natalie about how pharma companies can best implement gamification into their practices and what internal and external benefits they can gain.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Getting into gamification https://www.emg-gold.com/post/getting-into-gamification
The reality of the metaverse https://www.emg-gold.com/post/the-reality-of-the-metaverse
The difficulties of digital upskilling https://www.emg-gold.com/post/the-difficulties-of-digital-upskilling
In this episode, GOLD speaks to Lenias Hwenda, Founder and CEO, Medicines for Africa, and Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). Following on from GOLD’s recent ‘Pharma in South Africa’ feature, Lenias explains what the implementation of South Africa’s new healthcare system will mean for global pharma, as well as exploring genomics and market access. Alexander discusses his interest in pricing and access of pharmaceuticals, shares how value-based reimbursement is evolving and offers his thoughts on the new EU Health Technology Assessment procedure.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Pharma in South Africa https://www.emg-gold.com/post/pharma-in-south-africa
Margo Warren on global access to medicine https://www.emg-gold.com/post/podcast-margo-warren-on-global-access-to-medicine
Seeking solutions to low income, low access https://www.emg-gold.com/post/seeking-solutions-to-low-income-low-access
Operation vaccines: access all areas https://www.emg-gold.com/post/operation-vaccines-access-all-areas
In this special bonus episode, GOLD’s Editor Helena Beer reflects on the themes and her own key takeaways from this month’s NEXT Pharma Summit. What challenges are facing pharma, and what does the industry need to do to overcome these? Assistant Editor Isabel O’Brien also catches up with the event’s founder and chairman Dario Safaric to discuss his event highlights and thoughts on pharma’s future.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Digitalisation: moving past paperless https://www.emg-gold.com/post/digitalisation-moving-past-paperless
- A cautionary tale of innovation https://www.emg-gold.com/post/a-cautionary-tale
- A silver lining of patient centricity https://www.emg-gold.com/post/a-silver-lining-for-patient-centricity
- The difficulties of digital upskilling https://www.emg-gold.com/post/the-difficulties-of-digital-upskilling
In this episode, GOLD is joined by Emma Booth, Executive Director, Global Business Process and Insights Lead, R&D Strategy and Operations at Amgen. She discusses medical affairs communication and strategy, the power of data initiatives and the roadblocks that are preventing these from reaching their full potential, plus balancing leadership with nurturing one’s own aspirations.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Fresh clarity on RWE integration https://www.emg-gold.com/post/fresh-clarity-on-rwe-integration
Standing out in a crowd of content https://www.emg-gold.com/post/standing-out-in-a-crowd-of-content
Discussing a new dawn for data https://www.emg-gold.com/post/discussing-a-new-dawn-for-data
The RWD revolution https://www.emg-gold.com/post/the-rwd-revolution
In this episode, GOLD is joined by two of the pharmaceutical industry’s most unwavering mental health advocates: Wendy Bartie, Senior Vice President, US Oncology, Bristol Myers Squibb, and Courtney Billington, President, Janssen Neuroscience. They discern what resources pharma companies should be making available to their employees, what the industry’s role is in supporting patient mental health and how they manage their own mental wellbeing.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Pressure on UK government over mental health https://www.emg-gold.com/post/pressure-on-uk-government-over-mental-health
The driving seat of organisational change https://www.emg-gold.com/post/the-driving-seat-of-organisational-change
Making a difference in terminal diseases https://www.emg-gold.com/post/making-a-difference-in-terminal-diseases
Routine vaccinations: road to recovery https://www.emg-gold.com/post/routine-vaccinations-road-to-recovery
In this episode, Helena is joined by Klaus Legau, Senior Advisor, Social Sustainability at Leo Pharma. Klaus reveals the most important facets of a social sustainability strategy and where he believes the pharmaceutical industry is falling short in this respect, as well as offering expert advice to those starting out in policy campaigning.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
The driving seat of organisational change https://www.emg-gold.com/post/the-driving-seat-of-organisational-change
Novartis enhances social mobility commitments https://www.emg-gold.com/post/novartis-enhances-social-mobility-commitments
A joint mission for social justice https://www.emg-gold.com/post/a-joint-mission-for-social-justice
Setting the stage for a more equitable future https://www.emg-gold.com/post/setting-the-stage-for-a-more-equitable-future
In this episode, GOLD speaks with Luisa Luciani-Silverman, US Medical Head of Immuno-Oncology at AstraZeneca. She discusses all things medical affairs, delving into analytics, evidence generation, hiring candidates from non-traditional backgrounds and much more. Following on from GOLD's recent online poll, the teamalso hears from some special guests about their take on using TikTok as a pharma marketing tool.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Time to Turn to TikTok? https://www.emg-gold.com/post/time-to-turn-to-tiktok
Fresh clarity on RWE integration https://www.emg-gold.com/post/fresh-clarity-on-rwe-integration
The uphill recruitment battle https://www.emg-gold.com/post/the-uphill-recruitment-battle
The metrics of medical affairs https://www.emg-gold.com/post/the-metrics-of-medical-affairs
In this episode, GOLD is joined by Aaron Grandy, Associate Director, Alira Health, and Co-Founder, Precision Healthcare Consulting, who discusses the aim of his start-up, GoMed, on access and health outcomes in Africa. Plus, Laurence Woollard, Founder and Director, On The Pulse Consultancy, joins the team to explore the haemophilia landscape and share key messages for the pharma industry.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
New TV show brings "voice to voiceless" in Africa https://www.emg-gold.com/post/new-tv-show-brings-voice-to-voiceless-in-africa
The rare disease disparity https://www.emg-gold.com/post/the-rare-disease-disparity
Seeking solutions to low income, low access https://www.emg-gold.com/post/seeking-solutions-to-low-income-low-access
Bridging the digital health divide https://www.emg-gold.com/post/bridging-the-digital-health-divide
This week, Marc and Helena are back together in the studio once more, and to mark the midpoint of season two, GOLD’s Assistant Editor, Isabel O’Brien, joins them to check in on our guests’ predictions for 2022. Hear from Julie Ross, Kay Wesley and Jennifer Cain Birkmose as the team pours over their predictions to see if clinical trials have been drastically decentralised, whether hybrid events are here to stay and if pharma’s pandemic push for collaboration has continued.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Remote trials: replicating reality https://www.emg-gold.com/post/remote-trials-replicating-reality
Interview with Claire Skentelbery https://www.emg-gold.com/post/podcast-claire-skentelbery-director-general-europabio
Interview with Judy Stewart https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases
In this episode, GOLD is joined by Davidek Herron, Global Head of Digital, Roche, who discusses his journey from professional basketball player to pharma leader, including the lessons he has taken from sport into business. He also shares his unique take on digital transformation and the secret to job satisfaction.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
A Cautionary Tale https://www.emg-gold.com/post/a-cautionary-tale
"We’ve lost the focus that we had on routine vaccination of preventable diseases" https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases
A Debate On Digital Transformation https://www.emg-gold.com/post/a-debate-on-digital-transformation
"We need to create an equitable experience for all" https://www.emg-gold.com/post/we-need-to-create-an-equitable-experience-for-all
In this episode, GOLD is joined by Magnus Björsne, CEO, AstraZeneca BioVentureHub, who discusses the impact of the pandemic on innovation, collaboration and creativity within the industry. This episode also features a special diabetes-focused ‘Things you might have missed’, with news on novel management and monitoring technology for people living with diabetes.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Nurturing home-grown innovation in Europe https://www.emg-gold.com/post/nurturing-home-grown-innovation-in-europe
A recipe for success in European healthcare https://www.emg-gold.com/post/a-recipe-for-success-in-european-healthcare
A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech
The risks, rewards and future potential of biotechnology https://www.emg-gold.com/post/podcast-the-risks-rewards-and-future-potential-of-biotechnology
In this episode, GOLD is joined by Isabel Afonso, General Manager, Novartis Oncology China, who shares insights on the pharmaceutical landscape of the country and the potential of partnerships with multinational corporations, followed by a conversation with Dr Farid Khan, CEO and Founder, PharmaKure, about the vital ongoing need for drug development and the scientific details behind biopharmaceuticals.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Pharma in… China https://www.emg-gold.com/post/pharma-in-china
A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech
A heyday for mRNA https://www.emg-gold.com/post/a-heyday-for-mrna
The vast galaxy of neurology https://www.emg-gold.com/post/the-vast-galaxy-of-neurology
In this bonus episode, GOLD brings you the full feature-length interview with Claire Skentelbery, Director General, EuropaBio. She explores the contribution that biotech will have on Europe’s future and economic footprint, the preparedness of Europe to deliver biotech’s innovative therapies at scale, as well as the investment landscape for biotech-related SMEs.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech
Nurturing homegrown innovation in Europe https://www.emg-gold.com/post/nurturing-home-grown-innovation-in-europe
The hard sell of cell and gene therapies https://www.emg-gold.com/post/the-hard-sell-of-cell-and-gene-therapies
In this episode, we speak to Claire Skentelbery, Director General, EuropaBio, about the biotech revolution, including how biotech companies could contribute to the European economy in the future and the readiness of Europe to deliver these innovative solutions at scale. The GOLD team also discusses the biotech revolution from an investor’s perspective, exploring the risks and rewards of investing in therapies driven by biotechnology.
Click here to subscribe to the weekly newsletter for more insights from GOLD.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech
Nurturing homegrown innovation in Europe https://www.emg-gold.com/post/nurturing-home-grown-innovation-in-europe
The hard sell of cell and gene therapies https://www.emg-gold.com/post/the-hard-sell-of-cell-and-gene-therapies
In this episode, Dr Nigel Guest, CEO, Trifolium Consulting, speaks to GOLD about his experiences as a GP during the pandemic, interactions with the pharma field force and his thoughts on the future of preventative medicines. Helena and Isabel additionally discuss the importance of making disease awareness campaigns really matter.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: Pursuing a pathway of prevention https://www.emg-gold.com/post/pursuing-a-pathway-of-prevention Building Campaigns with Communities https://www.emg-gold.com/post/building-campaigns-with-communities Making a Difference in Terminal Diseases https://www.emg-gold.com/post/making-a-difference-in-terminal-diseases The Rare Disease Disparity https://www.emg-gold.com/post/the-rare-disease-disparity
In this special bumper episode to mark International Women’s Day, Helena is joined by Nikki Jones, Head of Diversity, Equity and Inclusion at the Healthcare Businesswomen’s Association, to discuss the role of this global celebration within the health space. The team also speaks to Aliya Omer, Vice President and Head of Global Portfolio and Program Strategy at Kite Pharma, about how she navigated gender biases through her career. And the episode is topped off with a deep dive into GOLD features on gender parity with Isabel O’Brien, Assistant Editor – it’s an episode not to be missed!
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
A discussion on the pandemic and gender parity https://www.emg-gold.com/post/a-discussion-on-the-pandemic-and-gender-parity
Diversity: from ideas to action https://www.emg-gold.com/post/diversity-from-ideas-to-action
Mind the pay gap https://www.emg-gold.com/post/mind-the-pay-gap
In this episode, GOLD talks to Liz Ashall-Payne, founder of ORCHA, a company that curates libraries of digital health apps for patients and healthcare professionals. She discusses the growing patient appetite for apps, the education that is needed for healthcare professionals and early considerations for pharma companies wishing to develop these solutions. GOLD also speaks to Dario Safaric, founder of the 'NEXT Pharma' conferences, about the upcoming ‘Next Normal’ event and pharma’s future in the metaverse.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Bridging the digital health divide https://www.emg-gold.com/post/bridging-the-digital-health-divide
- Spoonful of apps https://www.emg-gold.com/post/spoonful-of-apps
- Next Normal event https://nextpharmasummit.com/nextnormal/
In this episode, GOLD talks to Wayne Best, Chief Creative Officer, VMLY&R, who offers his insights on the innovative ‘I Will Always Be Me’ project with the MND Association – a fascinating and important cause with so much potential to inspire the pharma industry. But that’s not all! Join us to delve into the latest GOLD infographic on supply chain stability and hear the latest industry news you might have missed.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
- Risks to supply chain vulnerability – infographic https://www.emg-gold.com/_files/ugd/b8a9db_2fee0c32ea6940e69a36e4d939eedade.pdf
- Reacting to supply chain risks https://www.emg-gold.com/post/reacting-to-supply-chain-risks
- AI and Big Data at the forefront of pharma in 2022 https://www.emg-gold.com/post/ai-and-big-data-at-the-forefront-of-pharma-in-2022
- The latest GOLD issue, including the blockchain feature mentioned https://go.emg-gold.com/gold-20-access-form
The GOLD Podcast is back and better than ever! Tune into the first episode of Season 2 to hear the news you might have missed, exclusive extracts from GOLD’s catalyst interview with Judy Stewart, Senior Vice President and Head of US Vaccines, GSK, as well as a fascinating conversation with Independent Pharma Broker and blockchain enthusiast, Vincent Steine.
Click here to subscribe to the weekly newsletter for more insights from GOLD. https://www.emg-gold.com/subscribe
If you are interested in learning more about the topic areas discussed in this episode, check out the following content:
GSK warns against routine vaccine complacency https://www.emg-gold.com/post/gsk-warns-against-routine-vaccine-complacency
Avalere Study – ‘How COVID-19 Has Impacted US Adolescent and Adult Vaccine Utilization’: https://avalere.com/insights/how-covid-19-has-impacted-us-adolescent-and-adult-vaccine-utilization
Hear more from Judy Stewart: “We’ve lost the focus that we had on routine vaccination of preventable diseases” https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases
We’re back! The next season of the GOLD Podcast launches on 15th February with a brand new format, more high profile guests and fresh industry insights – subscribe now to be the first to join hosts Marc and Helena and hear new episodes.
For the season finale of the GOLD Podcast, we look back at our 'GOLD Medal Moments' from the past 12 months, revisiting interviews with some of our top guests. Marc and Helena pick out the most important and challenging topics from 2021, including combatting misinformation, the evolving role of medical affairs, improving access to medicine and producing results in times of crisis.
In this episode, we talk to Margo Warren, Head of Policy at the Access to Medicine Foundation, who offers her thoughts on the ever-present need for global access to medicine. Margo discusses her path into the fight for health equality, the importance of global vaccine distribution, the changing philosophies behind bringing a product to market, and the move from reactive to pre-emptive research and development.
Join us in kicking off the new year with a special episode of the GOLD podcast, welcoming back six of our previous guests to share their predictions for what 2022 could bring for the pharmaceutical industry. They discuss a broad spectrum of topics ranging from new tech trends and clinical trial developments, to improvements in diversity and inclusion and patient centricity.
In this special end-of-year round up episode, three of this year’s GOLD Podcast guests return to review 2021 in the pharmaceutical industry. They discuss topics ranging from industry reputation to vaccine access, and celebrate and critique the year just past, while also looking ahead to 2022.
In this episode, we talk to Catherine Owen, Head of Major Markets at Bristol Myers Squibb, who discusses her path into the pharmaceutical industry and the upcoming changes to its data policies. Catherine explores the collection and storage of data, how we can ensure data systems are in place for the next pandemic, methods to build a new data culture and her key takeaways from the past year in pharma.
This week, we reflect on the highlights from the pharmaceutical industry that took place in November, covering the latest in COVID-19 developments, the most notable mergers and acquisitions, the standout awareness campaigns, and the latest in research and development news.
We talk to Tamika Jean-Baptiste, Vice President and Chief Diversity Officer, Amgen, who discusses her lifelong passion for diversity both in the workplace and in life. Tamika explores the importance of aligning your purpose and your passion, how best to draw young people into pharma, leveraging employee resource groups, and the significance of filling your own cup before reaching for others.
We speak to Chumi Khurana, Global Head, Prostate Cancer Disease Area Stronghold, Janssen Oncology about her pathway into men’s health, the challenges and potential solutions in the realm of prostate disease, and her advice for family and caregivers on how best to support a loved one who is dealing with a prostate cancer diagnosis.
We talk to Dr Richard Kaszynski, Chief Medical Officer, AiPharma, who discusses the emerging role of antivirals in healthcare. He explores his work on the GUARDIAN program, the benefits of drug repurposing, the importance of keeping patients out of hospitals and his highlights from the past year.
This week, Tanja Dowe, CEO, Debiopharm Innovation Fund, discusses her passion for digital health tools. Drawing on her experience of investing in health technologies, she explores what it takes to be a successful entrepreneur, how these tools could improve life expectancies in cancer, and her highlights from a year of digital transformation for the pharmaceutical industry.
This week, we take a look back at the standout moments in the pharmaceutical industry from October, covering the latest in COVID-19 developments, the most notable mergers and acquisitions, marketing highlights, and the latest in research and development.
We talk to Dr Emma Roffe, Oncology Country Head, Takeda UK, and Eric Low, Founder, Myeloma UK, about the challenge of combination treatments. The two discuss a pair of whitepapers recently produced by Takeda, which uncover why challenges exist, why for so long it has been classified as ‘too hard to solve’, as well as potential solutions that could revolutionise this area of healthcare. Disclaimer: This episode is editorially owned by EMG GOLD.
We talk to Massimiliano Siciliano, Digital Solution Director Europe, Novartis, about the potential of digital solutions for the pharmaceutical industry’s stakeholders and commercial teams, the technology he is most excited about within pharma’s digital revolution, and his three key principles for building high performing teams.
We talk to Clare Hague, Senior Director, Haematology Market Access, Europe, the Middle East, and Africa, Janssen. She shares her perspective on the industry’s drug pricing challenges and opportunities, details alternative pricing systems that could improve access in low-to-middle-income countries, and explores the shifting market access landscape within oncology.
This week, we look back at the highlights in pharma throughout September, covering the latest in COVID-19 developments, the most notable mergers and acquisitions, marketing standouts, and the latest in research and development news.
We talk to Matt Atkinson, Global Projects Director, Reuters Events Pharma, and Megan Reutin, Global Head of Omnichannel Analytics, Grünenthal Group, about the upcoming Reuters Pharma 2021 Event. We get a sneak peek into the event's line-up, consider the future of virtual events, and explore the rapid digital transformation that has taken place over the past year.
We talk to Julie Ross, President, Advanced Clinical, about gender parity in the workplace in aid of International Equal Pay Day. In the discussion, she covers her journey to leadership, the importance of determination and resilience, and why gender parity in healthcare and life sciences is so essential.
We talk to Carol Lynch, Chief Business Officer, Sandoz, about how to increase the number of women in leadership positions in the pharmaceutical industry, the importance of mental health provisions in the workplace, and Sandoz's role in increasing access to biosimilars around the world.
We talk to Keren Leshem, Chief Executive Officer, OCON Healthcare about how she transformed OCON’s business strategy, the importance of educating women on their health and options, and how being mentored as well as acting as a mentor has shaped her career and outlook.
This week, we reflect on the highlights in pharma throughout August, covering the latest in COVID-19 therapy developments, the most notable mergers and acquisitions, marketing highlights, and the latest in research and development.
This week, we talk to Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haematology, Janssen, about the impact medical affairs can have on improving patient outcomes. He discusses the different approaches required to engage HCPs working in diabetes, immunology, and haematology, how to advance precision medicine, and steps that can be taken to improve the quality of life of those undergoing cancer treatment.
This week, we speak with Dr Jerome Kim, Director General, International Vaccine Institute, about vaccines. The conversation covers the nuances of the vaccine development process, the pharmaceutical industry's role in addressing vaccine hesitancy and refusal, and equitable distribution. He also shares his experience of working within the US military.
This week, we talk to Dirk Kosche, President, Established Markets, Astellas Pharma Europe Ltd, about turning innovation into value for patients, the role of the pharmaceutical industry in addressing health inequities, and his appreciation for the Japanese work culture.
This week, we reflect on the highlights in pharma throughout July, covering the latest in COVID-19 developments, the most prestigious mergers and acquisitions, marketing standouts, and the latest in research and development.
This week, we speak with Jennifer Cain Birkmose, Senior Pharmaceutical Leader in Market Access, Patient Access, and Patient Advocacy. She explores the idea of co-designing clinical trials and treatment with patients, discusses the concept behind reverse mentoring, and reveals how the rules of improvisation help her when leading teams.
This week, we talk to Vanessa Pott, Director, Global Patient Insights and Advocacy, Merck KGaA, about her path into patient advocacy, the importance of recognising and supporting informal and family carers, and an MS awareness campaign that saw Merck partner with the gaming platform, Twitch.
This week, we speak with Alexey Cherchago, Head of Sales Excellence Europe, Sandoz, about leadership, how the role of the medical sales representative has evolved, and what the ‘new normal’ will look like within pharma’s commercial teams.
This week, we reflect on the highlights in pharma throughout June, covering the latest in COVID-19 therapy developments, the most notable mergers and acquisitions, marketing highlights, and the latest in research and development.
This week, we talk to Denise Dewar, Digital Hub Director, Europe, Japan, and Canada, GSK. She discusses her transition from the whiskey industry to the pharmaceutical sector, the importance of viewing all customers first and foremost as people, and how digital transformation will improve patient outcomes in the future.
This week, we sit down with Ana Rita Ferreira, Region Europe Medical Director, Novartis, who discusses the challenges of delayed cancer care, her advocacy for women in STEM, and considers how the pharmaceutical industry can combat the challenge of misinformation as well as overcome bureaucracy.
This week, we speak to Lorena Kuri, Director of Clinical Trial Diversity Strategy, Bristol-Myers-Squibb, who discusses how to address underrepresentation in clinical trials, how teams can prioritise belonging, and how her experience as a board member of WOCIP has shaped her perspective and ambitions.
This week, we sit down with Rodrigo Garcia, Head of Patient Centricity, Recruitment and Retention, EMD Serono, who stresses the importance of onboarding diverse patient populations in clinical trials, explains what the challenges of patient retention are, and considers why virtual trials weren’t embraced sooner.
This week, we reflect on the highlights in pharma throughout May. We will be covering the latest in COVID-19 and vaccine developments, the most prominent mergers and acquisitions, marketing highlights, and the latest in research and development.
This week, the conversation with Former England Rugby Coach and Former Director of Sport, Team GB, Sir Clive Woodward continues. Sir Clive explains the importance of teams having aligned values, the rules of teamship and how to apply them within organisations, and shares his top book recommendations.
This week, we sit down with Former England Rugby Coach and Former Director of Sport, Team GB, Sir Clive Woodward. Sir Clive shares with us the concept of Lombardi time and how winning teams should embrace it, as well as how marginal gains can have an overall gross impact on success.
This week, we speak to Florent Edouard, Senior Vice President and Global Head of Commercial Excellence, Grünenthal Group, about his journey from finance to pharmaceuticals, the role of artificial intelligence in digital transformation, and wearing roller skates to work.
This week, we reflect on the key happenings in pharma throughout April. We will be covering the latest in COVID-19 and vaccine developments, the most prestigious mergers and acquisitions, the latest in research and development, and marketing highlights.
This week, we sit down with Dr Emily Pegg, Head of Medical Affairs UK, Takeda Oncology, to consider how the pharmaceutical industry's relationship with healthcare professionals is evolving, discuss the future of the medical affairs function, and hear how she encourages and supports personal development within the teams she leads.
This week, we sit down with Timothy White, Vice President and Head of Global Digital Commercial, Teva Pharmaceuticals, to explore the subject of digital transformation. He discusses the ‘four Es’ of digital content, shares insight from the news and education platform NeurologyBytes, and reflects on his time working in the music industry.
This week, we are joined by Paul Simms, Chief Executive, Impatient Health and Pharma Provocateur, who shares his experience of the past year, the importance of overcoming red tape in pursuit of innovation, and his predictions for the pharmaceutical industry in 2021.
This week, we reflect on March in pharma and the key happenings from the month. We will be covering the latest in COVID-19 and vaccine developments, the most prestigious mergers and acquisitions, the latest in research and development, and more.
This week, we sit down with Claudia Martinez, Research Programme Manager, Access to Medicine Foundation, who explains the methodology behind the Access to Medicine Foundation's 2021 Index, why access to medicine is still a challenge for the pharmaceutical industry, and how companies can adapt their processes to reach to most vulnerable patient populations.
This week, we talk to Rob Jekielek, Managing Director, The Harris Poll, to explore evolving public perceptions of the pharmaceutical industry, considering how the progress made during COVID-19 can be sustained and what is needed to ensure their reputation improves even further.
This week, we sit down with Jose Maria (Chema) Guido Avila, Global Lead HCP Marketing, Sanofi, to hear his thoughts on the importance of combating misinformation, what metrics are most appropriate to measure the success of virtual events, and why Germany should be on everyone’s travel list.
This week, we are joined by four esteemed guests from Ipsen's UK & Ireland team, including Asad Mohsin Ali, Managing Director, to discuss the fabric and value of high-performing teams, especially against a backdrop of the COVID-19 crisis.
This week, we reflect on February's month in the pharmaceutical industry, covering the latest in vaccine developments, the most promising mergers and acquisitions, and work at The European Commission which could encourage further international collaborations into 2021 and beyond.
This week, we speak to Uzair Qadeer, Chief Diversity Officer, Alexion, to reflect on his notable career as a HR futurist, understand how diversity and belonging are business imperatives for the pharmaceutical industry, and why Italy has been his favourite place to live to date.
This week, we talk to Kevin O’Brien, President, North America, Merz Therapeutics, about the intricacies of developing a treatment for a new indication, translating a company culture online, and leadership lessons he has learnt because of COVID-19. Please note the product discussed in this podcast has a black box warning and could result in potentially serious side effects.
This week, we speak to Ester Banque, Senior Vice President and Head of Intercontinental Commercial, Bristol-Myers Squibb, about her unique approach to leadership and team building, the importance of being visible on social media, as well as her passion for diversity and representation across the industry.
This week, we look back at January in pharma, covering the roll out of vaccine candidates, the pharmaceutical industry's first case of collaboration with Google, as well as the great progress being made in oncology and paediatric treatments for HIV.
This week, we speak to Kay Wesley, Chief Executive, Kanga Health, about the ethos of her agency, the power of pharma's digital transformation, and her passion for creating gender equality, particularly in light of inequalities revealed by COVID-19.
This week, we are talking to Nancy Globus, Vice President for Regulatory and Medicine Safety, Addison Whitney, about medication safety and product labeling, deconstructing how clear drug names and well-designed labels can prevent errors and protect patients all over the world.
This week, we are looking forward to the year ahead and casting five predictions for what the standout advancements and priorities will be for the pharmaceutical industry in 2021.
For the final episode of 2020, we look back at the past year in the pharmaceutical industry, reflecting on the COVID-19 milestones, the major appointments and acquisitions that have taken place, as well as pharma’s transition into digital and the substantial progress made in combatting Ebola, HIV, and Polio.
This week, we speak to Karen Moyse, Founder and Managing Director of mindset consultancy, KineticFuture Leadership. We discuss how to interrupt less and listen better, best practices for managing conflicting personalities at work, and her experience of running her own business through global recessions and now a pandemic.
This week, we speak to Isma Benattia, Vice President Europe Medical Affairs, Amgen about her work as a psychologist, harnessing technology to unlock better outcomes for patients, and the importance of diversity and inclusion in the workplace.
This week, we look back at the past month in pharma: an exciting time in which the vaccine race hit a fever pitch and companies pulled out all the stops to honour disease awareness months across a range of therapy areas.
This week, we speak to Arun Mahtani, Former Vice President, Channels Strategy and Digital Content, Teva Pharmaceuticals, about the lessons he applied from broadcasting to his career in pharma, how to design impactful patient initiatives, and the impact of digital transformation across both commercial and clinical trials.
This week, we speak to Kumaran Krishnan, Director, Medical Excellence and Digital Transformation, Teva Pharmaceuticals, about unlocking further potential in developed markets, the impact of COVID-19 on MSL KPIs, and building medical affairs teams that are fit for the future.
This week, we are joined by Pierre Bourdage, Global Head Biopharmaceuticals, Sandoz, who provides insight into the state and future of the biosimilars market, discusses how to adapt to 'the new normal', and shares the lessons he learnt as a member of the Canadian Grenadier Guards.
This week, we look back at the past month in pharma, focussing on some important mergers and acquisitions that have taken place, as well as all the latest COVID-19 treatment and vaccine news.
This week, we are joined by Patrick Romano, Co-founder and Partner, Eradigm Consulting, to discuss his experience as a biochemist, how to build pharmaceutical value propositions fit for the future, and how the industry can navigate the blurring of lines between pharma and public health.
This week, we speak to Ian Dorrian, President Communications Europe, Syneos Health, about his journey from the pharmaceutical industry to the agency world, what pharma can do to mitigate the spread of fake news, and how long-term use of virtual communication could affect product launches of the future.
This week, we are joined by Haider Alleg, Global Head of Digital Excellence, Ferring Pharmaceuticals. We discuss his entrepreneurial spirit, his fascination with Japanese business methodologies, and consider what both the pharmaceutical and financial sectors could stand to learn from one another.
This month, we reflect on some of the standout events from September in the pharmaceutical industry, highlighting shifting public perceptions of the industry, exploring the FDA's pushback against counterfeit medications, and providing an update on the latest COVID-19 vaccine developments.
This week, we speak to Fran Ayalasomayajula, Head of Population Health Portfolio, Worldwide Healthcare, HP. Fran discusses scaling technological adoption, thought leadership, and the positive impact technology will have on future population health.
This week, we sit down with Denice Torres, ex-Chief Strategy and Business Transformation Officer, Johnson & Johnson and Founder, The Mentoring Place and The Ignited Company. She discusses the importance of diversity and having a positive mindset, why being different is your secret weapon, and how to empower people and patients alike.
This week, we speak to Ben Hunt-Davis, Olympic rowing champion and CEO of the business performance consultancy, Will It Make The Boat Go Faster?, about the demands of professional sport, applying Olympic training principles to business, and how to use reviews to generate personal growth.
This week, we're celebrating 100 episodes of the EMG GOLD Podcast with a very special guest: the legendary businessman, Sir Martin Sorrell. Sir Martin talks about the importance of making decisions without delays, the power of being the best to become the biggest, and having a roadmap to lead you to your goals.
This month, we are focussing our round-up on COVID-19 vaccines, taking a look at three of the most advanced contenders and revealing the funding, purchasing, and clinical trial progress each has made in recent weeks.
This week, we speak to Nina Antinora, CEO of mindfulness company, Change It Up, about the importance of soft skills for both marketing and medical affairs professionals, how to prevent burnout, and ways to incorporate mindfulness into your daily schedule.
This week, we speak to Dario Safaric, Chairman of the NEXT Pharma Summit, about his journey starting a conference from scratch, Croatia's historical relationship with the pharmaceutical industry, and the future outlook for medical conferences in the post-COVID-19 era.
This week, we speak to Nigel Adkins, professional football manager, former player, and physiotherapist, about his career in football, the valuable lessons he has learnt about leadership, and the importance of routine in navigating challenging professional periods.
This week, we look at the past month in pharma, examining some important advancements and approvals in cancer and cardiology treatments, as well as the key COVID-19 vaccine progress.
This week, we speak to Dr John Michels, former NFL player turned renowned interventional pain specialist, who explores the mindset it takes to become successful, how to be the master of your own outcomes, and the science behind negative habit cycles and how to beat them.
This week, we talk to Dr Steve Ingham, leading performance scientist and founder of the performance consultancy, Supporting Champions, about his work with the British Olympic team, how to earn the respect of high performers, and what businesses can learn from the mindsets of professional athletes.
This week, we sit down with Mircea Cubillos, Vice President Hematology EMEA, Commercial Strategy Lead, Janssen, to discuss his lengthily career at Janssen, progression in oncology during COVID-19, and cultivating healthy habits during lockdown.
Spencer sits down with Will Champion, drummer for the band Coldplay, to discuss the mindset it takes to become and remain successful. Together, they explore how to cultivate effective collaboration, as well as how to sustain passion and creativity over long stretches of time.
This week, we talk to Dr Gino Martini, Chief Scientist, Royal Pharmaceutical Society, about the rapid data generation of COVID-19, the value of digital for HCPs, and why he thinks there will be much to reflect on after the pandemic has passed.
We spoke with Olli Rundgren, CEO, Psyon Games, about the power of games and how they can positively impact health and behaviour. Olli discusses the formation of habits, the opportunity for education and data collection, and Psyon Games' WHO endorsed game ‘Antidote’.
This week, we interview Sarah Rickwood, Vice President of Thought Leadership and Marketing, IQVIA, about the key trends and challenges that have shaped the past decade in pharma. We discuss RWE, multi-channel marketing, and the future of drug launch post-COVID-19.
This week, we look back at the past month in pharma, and in celebration of our new infographic 'Pharma's Mission to Combat Coronavirus', we examine key treatment developments, vaccine news, and donations made by the industry.
This week, we are joined by Grant Cardone, renowned sales expert, motivational speaker, author, and property tycoon. Grant shares his approach to maintaining a positive mindset, considers the future of entrepreneurship, and offers advice on how to advance your business in a crisis.
This week, we speak to social media experts, Chloe Partikas and Rick Evans, from Ogilvy Health UK, who share insights from their 2020 Social Check-up, which looked into the social behaviours of the pharma industry.
This week, we talk to Biljana Naumovic, VP Oncology EMEA, Commercial Strategy Lead, Janssen, about her journey from physician to pharma leader and how she sees the role of commercial evolving as a result of COVID-19.
This month, we bring you a roundup of the COVID-19 vaccine and drug development news, plus some positive advancements in the field of oncology.
This week, we speak to Emma Clayton, CEO of Grey Bear Consultancy, about the journey to starting her own agency, pharma communications in the COVID-19 era, and empowering women to succeed in the workplace.
Michaila is joined by Pierre van Weperen, Chief Commercial Officer of Grow Biotech. Together they explore the potential of medicinal cannabis and consider the differences between working in big pharma vs in a start-up...
This week, we speak to Dr. William Soliman, Chairman and CEO, of the Accreditation Council for Medical Affairs, about establishing industry benchmarks, what it is like to join the field now, and what it means to be a futurist in medical affairs.
Sen looks back at the past month in pharma, examining the progress of treatment and vaccine efforts against COVID-19, and highlighting some positive industry news that has emerged despite the on-going pandemic.
In this special episode, Spencer interviews an NHS doctor on the frontline of COVID-19 and a patient who has just recovered from the virus, unpacking this unprecedented situation from both perspectives.
This week, Spencer sits down with Claire Gillis, International CEO, WPP Health Practice, who discusses WPP's work with the ABC Global Alliance, how the communications role can transform patient outcomes, and the proudest moments from her career so far.
Sen is joined in the studio by Arpita Pani, Senior Commercial Governance, Digital and e-commerce lead at Ferring Pharmaceuticals. Arpita discusses the evolution and future of digital marketing in pharma, including the industry's use of social media.
Dan discusses digital health with Julien De Salaberry, an expert in health tech, who has worked across the pharma and start-up sectors, striving to solve healthcare pain points with technological innovation.
We reflect on EMG-Health's recent trip to business guru, Grant Cardone's 10X Growth Conference in Las Vegas. With CEO, Spencer Gore, and Performance Manager, Darren Brace, revealing their key highlights and takeaways from the event.
Following the coronavirus outbreak, European congress attendance is down and events are being postponed. We sit down with Professor Jonathan Sackier to dispel the myths around the virus and discuss why it's important for pharma to find alternative ways of sharing their research.
This week, it's time to look back at the past month in pharma, examining the industry response to coronavirus, potential blockbuster drugs of 2020 and some innovative disease awareness campaigns that score high on creativity.
Spencer is joined by the Executive Chairman of Brandon Medical, Graeme Hall, who reveals how the medical device industry is evolving and deconstructs the impact of 4K and smart operating theatres on the surgical process.
Sen is joined by a special guest on this week's podcast: Claudia Adreani, Business Head of Customer Excellence at Boehringer Ingelheim. Amongst a plethora of topics, they discuss the evolving world of marketing in pharma and Claudia's gymnastics pedigree!
Spencer is joined by eyeforpharma Chairman Paul Simms to discuss the upcoming eyeforpharma Barcelona 2020 event, as well as the importance of pharma finding and communicating their purpose to the public.
The new year has seen the pharma industry's involvement in a number of issues of global significance. And this week, Sen takes us through initiatives pharma companies have begun in January to combat the coronavirus outbreak and climate change.
Sen chats to James, co-founder of social media consultancy, Social Tree Global. They discuss the SMIP event he hosted in November and explore why pharma should overcome their social media fears to create meaningful relationships with HCPs and patients.
Isabel is joined again by Michaila to discuss her recent GOLD article, 'Marketing Forecast: Cloudy with a Chance of AI', which looks at the potential of AI to help pharma marketers streamline budgets and target with better accuracy...
Spencer is joined by Kris Sterkens, Company Group Chairman (Europe, Middle East and Africa) of Janssen and they discuss a range of topics including the evolving sales landscape, learning from tech start-ups and patient-centric drug development.
Sen casts some predictions for the coming year, looking at how the industry may respond to the rise of medicinal cannabis, as well as patient demand for easier access to clinical trials.
Sen reflects on the year 2019 and all the exciting news, challenges and trends that have been taking place in the pharmaceutical industry.
Sen and Isabel discuss how the pharmaceutical industry can refresh their traditional sales and marketing models, plus reveal how storytelling can be the key to engaging colleagues with radical change.
We chat to CEO of Trifolium Consulting and GP of over 30 years, Nigel Guest. He shares his passion for developing medical devices, reflects on the evolution of the NHS and considers the changing role of the GP in an increasingly digital world.
Isabel and Michaila reflect on an article featured in GOLD 07 that considers the importance of mental health and pharma's internal duty of care to employees.
Sen takes us through a positive month of corporate responsibility in pharma, highlighting the bold steps the industry is taking to improve lives on both a global and local scale.
This week, the EMG-Health Podcast features Jonathan interviewing Montel Williams. They touch upon Montel's military and entertainment career and discuss the MS diagnosis that led to his advocacy of cannabis as a legitimate means of therapeutic treatment.
Sen and Kirstie offer a preview into what our readers can expect from the November issue of GOLD magazine. They reveal the identity of our Catalyst interviewee and discuss some of the exciting topics, including AI and the power of happiness...
This week, EMG's COO, Dan Scott welcomes Eric Bouilloux, Chief of Staff, Global Medical Affairs, Ipsen to the EMG office. Eric discusses his career path to his current position, and also shares his views on the evolution of medical affairs.
This week, Sen takes us through a number of important announcements regarding changes to top executive positions in pharma during October. She also considers the impact these could have for the industry in the near future.
Two of the GOLD editorial team, Isabel and Michaila, explore the long-awaited reform of the European patent system: Unitary Patent. What does it mean for pharma? And what has led to its delay?
Kirstie and Michaila discuss the eyeforpharma Patient Summit and Marketing and Customer Innovation conference that took place in London on 15th and 16th October 2019.
In this episode, Michaila and Kirstie look at exciting innovations that are enabling disabled people to live independently and discuss the potential role pharma could play in this area in the future.
Debuting on this week's EMG Podcast is Isabel and Michaila from the GOLD editorial team. Together they discuss the rise and influence of the podcast and why pharma should be embracing the medium.
Sen takes us through some particularly eye-catching stories from the pharma industry in September. This includes developments in emerging areas such as medicinal marijuana, digital therapeutics, and AI technology.
This week, we hear the thoughts of Andrea Palmer, President of Publicis Health Media, on a range of topics, including how the pharma industry can fulfil evolving consumer expectations, plus her personal ambitions and career highlights to date.
This week, eyeforpharma Chairman Paul Simms visits the EMG offices to chat to Spencer about the upcoming eyeforpharma patient and marketing conferences in London in October, as well as his perspective on recent trends in the pharma industry.
In this episode, Sen and Kirstie discuss the increasingly influential Generation Z. They firstly analyse the unique characteristics of this population before looking at the methods pharma can use to engage them most effectively.
In this week's episode, Sen takes a look at some of the biggest news stories relating to the pharma industry in August. This includes reported sales revenue figures for Quarter 2 of this year as well as the announcement of major commercial agreements.
Spencer is joined by EMG's Head of Operations, Keith Moule, a former Team GB canoeist. They discuss how the lessons from working as a team in sport can be applied to business, drawing on personal experiences they've had in both areas.
This week, Sen and Kirstie meet up with Asad Mohsin Ali, General Manager of Ipsen's UK and Ireland office. Topics include Asad's unconventional route into pharma, leadership skills in pharma, working in different countries, and much more.
Sen is joined by a first timer to the podcast this week, our Editorial Administrator, Kirstie Turner, to discuss the content readers can expect from the upcoming edition of GOLD. They also reveal the infographic topic and who our catalyst interviewee is.
Head of Publishing Sen is back with a review of the month of July in pharma. In this episode, she takes a look at new appointments and updates of executive positions in the industry.
Spencer is joined by Dan to talk about the structure of EMG-Health's quarterly planning meetings. The pair discuss successes and challenges from the quarter and the main focus for the company in the next few months.
This week, Spencer and Dan discuss the value of self-development books. They demonstrate the importance of reading as part of a self-development plan and analyse the books that have been particularly impactful to their personal growth so far this year.
In this week's episode, Spencer tells Dan about attending the brilliant ScaleUp Summit and the speakers that inspired him there. Spencer delves into the importance of trust, which was a popular topic at the event.
This week, Sen takes a look back at news from the pharma industry in the month of June. In particular, she focusses on exciting new clinical trial results that were presented at a number of health conferences across various therapeutic areas.
This week, our Head of Publishing Sen takes us through Amy Nicole Nayar's fantastic talk, from the eyeforpharma Philadelphia event, on patient centricity, with a focus on communication within companies.
Spencer, Sen, and Louise are all in the studio this week, as they discuss their experiences and highlights from this year's Cannes Lions conference. They also touch on what will be included in the review of the event, to be published in August.
This week, Sen and Louise discuss the infographic published in the most recent edition of GOLD. This displays a breakdown of all new drug approvals by the EMA and FDA in 2018, highlighting examples of unique therapies now available for patients.
Sen is back with a review of the month of May in pharma. In this episode, she takes a look at the large number of investments and expansions announced within the industry in the past month.
With the 2019 Cannes Lions conference just around the corner, Sen reflects on insights from two people we spoke to at last year's event: Gwenan White, UK Director of Communications at Abbvie and Eric Peacock, Co-Founder and CEO of MyHealthTeams.
On this week's episode, Sen and Louise discuss one of the biggest topics in the pharma industry right now: Gene and cell therapy. They outline the issues that pharma need to solve ensure these are accessible to all patients.
In this week's episode, Daniel De Schryver, Patient Engagement & Advocacy Lead, EMEA at Janssen, talks to us about his work in ensuring pharma collaborate increasingly closely with patients and the past experiences that drove this passion.
This week Sen and Louise discuss the upcoming issue of GOLD, which is out on the 30th May. They talk about some of the article topics taken from this year's eyeforpharma conference in Barcelona and reveal our catalyst interview for this edition.
Sen is back in the hotseat for this week's episode as she reviews the month of April in pharma. She focusses on recent financial results in the industry and provides details of an innovative new pricing method that has been announced.
In this week's episode, Spencer is once again joined by Dan as the pair review the 7th Business Excellence Forum, held earlier this month in Telford, UK. They detail the speakers and messages that made the biggest impression on them.
Spencer is joined by a new face this week, EMG's Senior Project Director, Daniel Healy. The pair review the EMG's 5th Annual Company Ball from a few weeks ago, an event which included a talk from a Gold medal winning Olympian and the EMG Awards.
Neira from our design team debuts on the podcast this week, joining Sen in the hotseat. Together, they discuss the insights they gained from this year's Wired Health conference in London, an event which never fails to disappoint.
This week, Sen and Louise talk Brexit; in particular, the potential effect the UK's departure from the EU could have on the life-sciences sector, outlining insights from key stakeholders.
This week, Sen takes a look back at major stories that have taken place in the pharma industry in March. Partnership with tech companies was a big theme throughout the month, and Sen outlines some key examples and the impact these could have on patients.
In this week's episode, Spencer is joined by Louise to review the eyeforpharma conference in Barcelona that was attended by the EMG team earlier this month. Hear about the most important topics and themes that were discussed at the event.
This week, we are delighted to speak to one of the leading female voices in the pharma industry - Heather Moses, Head of Medical Affairs: Oncology at Roche. Heather shares her views on a number of pertinent topics in pharma.
This week, Performance Manager Darren joins Spencer to reflect on a recent conference they both attended: Grant Cardone’s 10X conference in Miami. Tune in to hear what the movement is, conference highlights, and much more.
This Friday is International Women’s Day! We are celebrating here at EMG with the Healthcare Businesswomen’s Association’s UK President, Andreea Apostol. Listen in to this episode to hear why she became a gender parity advocate, how the leadership path can be strengthened for women, how the industry can attract and retain women more effectively at senior-level positions, and much more! HBA article in GOLD 4: https://www.emg-gold.com/articles/stalled-progress-requires-bold-action-for-gender-parity
With eyeforpharma just around the corner, we reflect back on key interviews with industry leaders at last year’s conference. Listen in to hear insights Dr Amy Nicole Nayar Head of Global Patient Relations at AbbVie, and Houda Kamoun Chief Strategy & Marketing Officer at Aptus Health.
Let us know if you’re attending this year at @EMG_GOLD or lousie.rogers@emjreviews.com
Our head of publishing Sen Boyaci is joined by Louise Rogers to discuss the latest issue of GOLD magazine which is out in just 10 days! Hear what they have to say about the infographic, the catalyst interview, and Sen's favourite article.
Subscribe here to receive the issue for free: www.emg-gold.com/subscribe
The editorial team for GOLD meet up to discuss the latest issue of GOLD magazine, which is out on the 28th of Feb. Listen in to find out what's in store from digital opinion leaders to tackling neglected tropical diseases.
Make sure to subscribe at: www.emg-gold.com
Sen is back and joined by Louise to discuss China and the pharmaceutical industry. Listen to hear them discuss reasons behind the nations recent growth, medical affairs talent, the risk of protectionism, and much more.
Visit www.emg-gold.com to read the article on China and Interview with Victoria Elegant from Amgen on the 28th of Feb!
Chairman of eyeforpharma, Paul Simms visits the London office to join Spencer on this week's episode. Tune in to find out more about Paul, how he intends to shake-up the phama industry by inspiring creativity, his involvement with Humanity.co, and much more!
Visit wwww.eyeforpharma.com/barcelona/ to register for tickets and find out more about eyeforpharma's Barcelona conference in March!
Listen in to this week's episode to hear how Performance Management Consultant and Team GB Coach, Keith Moule applies his sporting mentality to business. From setting your goals to making every day count, this isn't one to be missed.
This week, Steve Clarke, Chief Commercial Officer at addvantage visits the EMG London office to talk to Spencer. Tune in to hear about his 30 years of experience in sales and marketing, an encounter which changed his life, and what he considers his biggest successes.
Spencer is back this week with Sen to talk about new year's resolutions for 2019. Tune in to hear about topics such as: deciding on a goal which suits you, planning it, and what to do when you've picked the wrong goal.
Happy New Year and welcome to the first episode of 2019! Listen in to hear what Sen and Louise have to say about the trends predicted for pharma's year ahead, these range from drug launches to what talent looks like.
This week, Sen is joined by our internal recruiter Joe, who shares his insights on the industry's current war for talent and the disruption it is set to face!
This week, tune in to hear what being truly 'innovative' means to our EMG hosts, Sen and Spencer, and why it is so important for any industry to flourish.
Spencer Joins Sen this week to discuss content marketing and all things social media! Join our hosts, as they speculate on the role of different social platforms and ways to produce useful and relevant content for your target audience.
Hosts
Spencer: @SJGore
Sen: @SenBoyaci
This week, Sen is joined by a new guest, Louise! Together, they go over the pharma industry’s 2018, including: the $62bn Shire/Takeda deal, CAR-T therapy approvals, Amazon entering the realm of pharma, the war for talent, and much more.
Hosts
Sen @SenBoyaci
Louise @EMG_GOLD
Check out the Pharma’s Year in Review: 2018 Infographic: www.emg-gold.com/infographic
Sen provides us with key insights from the Financial Times Global Pharmaceutical and Biotechnology Conference 2018. Tune in to hear about notable speaker sessions, the main takeaways, and some advice for getting the most out of events like these! Subscribe to GOLD magazine here: www.emg-gold.com
Hosts
Spencer @SJGore
Sen @SenBoyaci
GOLD III is on its way! In this episode, Spencer asks Sen about the upcoming and last issue of GOLD for 2018! This will include thoughts on the eyeforpharma Marketing and Customer Innovation and Patient Summit 2018, held in London last month. Sen also gives us a sneak-peek into the content that we can expect from this non-traditional and challenging issue. Grab a copy on November 29th at www.emg-gold.com and don’t forget to subscribe to ensure you don’t miss out on future issues!
Hosts
Spencer @SJGore
Sen @SenBoyaci
Interested in becoming a better you through personal development? This week, Spencer & Sen speak on the importance of personal development and getting those 10,000 hours in! Tune in to hear about lessons learned from successes and failures, BHAGS (Big Hairy Audacious Goals), book recommendations, and most importantly, how to structure your goals and incorporate them into your lives both inside and outside of work!
Make sure to develop yourself by signing up to GOLD magazine: www.emg-gold.com/
Hosts
Spencer @SJGore
Sen @SenBoyaci
Sen joins Spencer this week to debrief on his latest blog post ‘Maximising the Return from Your Symposium’. He talks us through his extensive experience with symposiums and the critical steps that medical affairs and marketing teams can take to ensure success. This encompasses topics such as benchmarking your net promoter score, repurposing content, the value of eblasts, avoiding common mistakes, and nailing those little things which have a huge impact!
Interested in running a campaign like this? Visit European Medical Media Website and get in touch via: www.europeanmedical-media.com/
Online blog: www.europeanmedical-group.com/omnipresen…symposium/
Hosts
Spencer @SJGore
Sen @SenBoyaci
Issue II of GOLD magazine is out! Listen in to this week’s episode to hear why GOLD is non-traditional and different. Covering the Cannes Lions’ health track, find out what Spencer made of the world-renowned event as a Cannes first-timer and what you can expect to find inside the latest issue!
Don’t forget to subscribe on our website to receive all of that great stuff into your inbox, free of charge: www.emg-gold.com
Hosts
Spencer @SJGore
Sen @SenBoyaci
This week, Spencer and Sen talk core values. Explaining how they are aligned with work, what they mean for EMG as a company. Key topics cover examples of inspiring pro-activity, admirable organisations, and finding your value fit in the world of work.
Find us at europeanmedical-group.com & emg-gold.com
Hosts
Spencer @SJGore
Sen @SenBoyaci
On our very first podcast episode, we interview Spencer Gore our CEO, to define EMG, EMJ & GOLD. Listen in to hear about his motivations for starting up the European Medical Group and what motivates him to get up on a cold winter’s morning! Find out more at europeanmedical-group.com & read our latest edition of GOLD at: emg-gold.com
Hosts:
Spencer Gore Twitter: @SJGore
Sen Boyaci Twitter: @SenBoyaci